ID   SCN1A_HUMAN             Reviewed;        2009 AA.
AC   P35498; E9PG49; Q16172; Q585T7; Q8IUJ6; Q96LA3; Q9C008;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   08-DEC-2000, sequence version 2.
DT   18-JUN-2025, entry version 242.
DE   RecName: Full=Sodium channel protein type 1 subunit alpha;
DE   AltName: Full=Sodium channel protein brain I subunit alpha;
DE   AltName: Full=Sodium channel protein type I subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.1;
GN   Name=SCN1A {ECO:0000312|HGNC:HGNC:10585}; Synonyms=NAC1, SCN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GEFSP2 MET-875 AND
RP   HIS-1648.
RX   PubMed=10742094; DOI=10.1038/74159;
RA   Escayg A., MacDonald B.T., Meisler M.H., Baulac S., Huberfeld G.,
RA   An-Gourfinkel I., Brice A., LeGuern E., Moulard B., Chaigne D., Buresi C.,
RA   Malafosse A.;
RT   "Mutations of SCN1A, encoding a neuronal sodium channel, in two families
RT   with GEFS+2.";
RL   Nat. Genet. 24:343-345(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Jeong S.-Y., Goto J., Kanazawa I.;
RT   "Cloning of cDNA for human voltage-gated sodium channel alpha subunit,
RT   SCN1A.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Sugawara T., Mazaki E.M., Yamakawa K.;
RT   "Homo sapiens neuronal voltage-gated sodium channel type I (Nav1.1) mRNA.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), VARIANT THR-1067, AND
RP   ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RA   Ouchida M., Ohmori I.;
RT   "Isoforms of human sodium channel SCN1A gene.";
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1335-1428.
RX   PubMed=8062593; DOI=10.1159/000133818;
RA   Malo M.S., Blanchard B.J., Andresen J.M., Srivastava K., Chen X.N., Li X.,
RA   Jabs E.W., Korenberg J.R., Ingram V.M.;
RT   "Localization of a putative human brain sodium channel gene (SCN1A) to
RT   chromosome band 2q24.";
RL   Cytogenet. Cell Genet. 67:178-186(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1518-1940.
RC   TISSUE=Brain;
RX   PubMed=1317301; DOI=10.1016/0014-5793(92)80476-w;
RA   Lu C.-M., Han J., Rado T.A., Brown G.B.;
RT   "Differential expression of two sodium channel subtypes in human brain.";
RL   FEBS Lett. 303:53-58(1992).
RN   [8]
RP   INTERACTION WITH FGF13.
RX   PubMed=21566136; DOI=10.1074/jbc.m111.245803;
RA   Wang C., Wang C., Hoch E.G., Pitt G.S.;
RT   "Identification of novel interaction sites that determine specificity
RT   between fibroblast growth factor homologous factors and voltage-gated
RT   sodium channels.";
RL   J. Biol. Chem. 286:24253-24263(2011).
RN   [9]
RP   ACTIVITY REGULATION.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G., Wickenden A.D.,
RA   Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [10]
RP   ACTIVITY REGULATION, AND SITE SER-1574.
RX   PubMed=28428547; DOI=10.1038/s41598-017-01129-0;
RA   Wingerd J.S., Mozar C.A., Ussing C.A., Murali S.S., Chin Y.K.,
RA   Cristofori-Armstrong B., Durek T., Gilchrist J., Vaughan C.W., Bosmans F.,
RA   Adams D.J., Lewis R.J., Alewood P.F., Mobli M., Christie M.J., Rash L.D.;
RT   "The tarantula toxin beta/delta-TRTX-Pre1a highlights the importance of the
RT   S1-S2 voltage-sensor region for sodium channel subtype selectivity.";
RL   Sci. Rep. 7:974-988(2017).
RN   [11]
RP   INTERACTION WITH TMEM233.
RX   PubMed=37117223; DOI=10.1038/s41467-023-37963-2;
RA   Jami S., Deuis J.R., Klasfauseweh T., Cheng X., Kurdyukov S., Chung F.,
RA   Okorokov A.L., Li S., Zhang J., Cristofori-Armstrong B., Israel M.R.,
RA   Ju R.J., Robinson S.D., Zhao P., Ragnarsson L., Andersson A., Tran P.,
RA   Schendel V., McMahon K.L., Tran H.N.T., Chin Y.K., Zhu Y., Liu J.,
RA   Crawford T., Purushothamvasan S., Habib A.M., Andersson D.A., Rash L.D.,
RA   Wood J.N., Zhao J., Stehbens S.J., Mobli M., Leffler A., Jiang D.,
RA   Cox J.J., Waxman S.G., Dib-Hajj S.D., Gregory Neely G., Durek T.,
RA   Vetter I.;
RT   "Pain-causing stinging nettle toxins target TMEM233 to modulate NaV1.7
RT   function.";
RL   Nat. Commun. 14:2442-2442(2023).
RN   [12] {ECO:0007744|PDB:7DTD}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.30 ANGSTROMS) IN COMPLEX WITH SCN4B,
RP   TOPOLOGY, DISULFIDE BONDS, GLYCOSYLATION AT ASN-338; ASN-1378; ASN-1392 AND
RP   ASN-1403, CHARACTERIZATION OF VARIANT DRVT VAL-1339 AND ARG-1658, AND
RP   CHARACTERIZATION OF VARIANT FMH3 LEU-1499.
RX   PubMed=33712547; DOI=10.1073/pnas.2100066118;
RA   Pan X., Li Z., Jin X., Zhao Y., Huang G., Huang X., Shen Z., Cao Y.,
RA   Dong M., Lei J., Yan N.;
RT   "Comparative structural analysis of human Nav1.1 and Nav1.5 reveals
RT   mutational hotspots for sodium channelopathies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [13]
RP   VARIANTS GEFSP2 VAL-188; LEU-1353 AND MET-1656, AND VARIANTS THR-1067 AND
RP   GLY-1928.
RX   PubMed=11254444; DOI=10.1086/319516;
RA   Wallace R.H., Scheffer I.E., Barnett S., Richards M., Dibbens L.,
RA   Desai R.R., Lerman-Sagie T., Lev D., Mazarib A., Brand N., Ben-Zeev B.,
RA   Goikhman I., Singh R., Kremmidiotis G., Gardner A., Sutherland G.R.,
RA   George A.L. Jr., Mulley J.C., Berkovic S.F.;
RT   "Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy
RT   with febrile seizures plus.";
RL   Am. J. Hum. Genet. 68:859-865(2001).
RN   [14]
RP   VARIANT GEFSP2 ARG-1204.
RX   PubMed=11254445; DOI=10.1086/319524;
RA   Escayg A., Heils A., MacDonald B.T., Haug K., Sander T., Meisler M.H.;
RT   "A novel SCN1A mutation associated with generalized epilepsy with febrile
RT   seizures plus -- and prevalence of variants in patients with epilepsy.";
RL   Am. J. Hum. Genet. 68:866-873(2001).
RN   [15]
RP   VARIANTS DRVT 222-ARG--LYS-2009 DEL AND PHE-986.
RX   PubMed=11359211; DOI=10.1086/320609;
RA   Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C.,
RA   De Jonghe P.;
RT   "De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic
RT   epilepsy of infancy.";
RL   Am. J. Hum. Genet. 68:1327-1332(2001).
RN   [16]
RP   VARIANTS GEFSP2 ALA-1428 AND VAL-1685.
RX   PubMed=11524484; DOI=10.1212/wnl.57.4.703;
RA   Sugawara T., Mazaki-Miyazaki E., Ito M., Nagafuji H., Fukuma G.,
RA   Mitsudome A., Wada K., Kaneko S., Hirose S., Yamakawa K.;
RT   "Na(v)1.1 mutations cause febrile seizures associated with afebrile partial
RT   seizures.";
RL   Neurology 57:703-705(2001).
RN   [17]
RP   VARIANT GEFSP2 THR-1270.
RX   PubMed=11756608; DOI=10.1212/wnl.57.12.2265;
RA   Abou-Khalil B., Ge Q., Desai R., Ryther R., Bazyk A., Bailey R.,
RA   Haines J.L., Sutcliffe J.S., George A.L. Jr.;
RT   "Partial and generalized epilepsy with febrile seizures plus and a novel
RT   SCN1A mutation.";
RL   Neurology 57:2265-2272(2001).
RN   [18]
RP   VARIANTS DRVT CYS-902; CYS-931; PRO-1265; PHE-1289 DEL; MET-1390; ARG-1434;
RP   ARG-1450; CYS-1648 AND ARG-1674 AND ILE-1909, AND VARIANT THR-1067.
RX   PubMed=12083760; DOI=10.1016/s0006-291x(02)00617-4;
RA   Ohmori I., Ouchida M., Ohtsuka Y., Oka E., Shimizu K.;
RT   "Significant correlation of the SCN1A mutations and severe myoclonic
RT   epilepsy in infancy.";
RL   Biochem. Biophys. Res. Commun. 295:17-23(2002).
RN   [19]
RP   VARIANTS DRVT GLY-103; ILE-112; TRP-265; ASP-343; VAL-960; ILE-985;
RP   ARG-1231; LEU-1263; ASP-1685; 1807-MET--GLU-1810 DEL; GLY-1812 AND
RP   SER-1831, VARIANTS ICEGTC SER-808; ARG-979; ALA-983; ILE-1011; PHE-1611;
RP   SER-1632; ILE-1709 AND LEU-1808, AND VARIANT THR-1067.
RX   PubMed=12566275; DOI=10.1093/brain/awg053;
RA   Fujiwara T., Sugawara T., Mazaki-Miyazaki E., Takahashi Y., Fukushima K.,
RA   Watanabe M., Hara K., Morikawa T., Yagi K., Yamakawa K., Inoue Y.;
RT   "Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable
RT   childhood epilepsies with frequent generalized tonic-clonic seizures.";
RL   Brain 126:531-546(2003).
RN   [20]
RP   VARIANTS GEFSP2 CYS-790 AND THR-1852.
RX   PubMed=12919402; DOI=10.1046/j.1528-1157.2003.22503.x;
RA   Annesi G., Gambardella A., Carrideo S., Incorpora G., Labate A.,
RA   Pasqua A.A., Civitelli D., Polizzi A., Annesi F., Spadafora P.,
RA   Tarantino P., Ciro Candiano I.C., Romeo N., De Marco E.V., Ventura P.,
RA   LePiane E., Zappia M., Aguglia U., Pavone L., Quattrone A.;
RT   "Two novel SCN1A missense mutations in generalized epilepsy with febrile
RT   seizures plus.";
RL   Epilepsia 44:1257-1258(2003).
RN   [21]
RP   VARIANT GEFSP2 VAL-188.
RX   PubMed=12576172; DOI=10.1016/s0920-1211(02)00259-0;
RA   Cossette P., Loukas A., Lafreniere R.G., Rochefort D., Harvey-Girard E.,
RA   Ragsdale D.S., Dunn R.J., Rouleau G.A.;
RT   "Functional characterization of the D188V mutation in neuronal voltage-
RT   gated sodium channel causing generalized epilepsy with febrile seizures
RT   plus (GEFS).";
RL   Epilepsy Res. 53:107-117(2003).
RN   [22]
RP   VARIANTS DRVT HIS-393; GLN-939; ARG-959; ARG-1434; SER-1661 AND GLU-1749.
RX   PubMed=12754708; DOI=10.1002/humu.10217;
RA   Claes L., Ceulemans B., Audenaert D., Smets K., Loefgren A., Del-Favero J.,
RA   Ala-Mello S., Basel-Vanagaite L., Plecko B., Raskin S., Thiry P.,
RA   Wolf N.I., Van Broeckhoven C., De Jonghe P.;
RT   "De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of
RT   infancy.";
RL   Hum. Mutat. 21:615-621(2003).
RN   [23]
RP   VARIANT GEFSP2 CYS-1657, CHARACTERIZATION OF VARIANTS GEFSP2 LEU-1353;
RP   MET-1656; CYS-1657 AND VAL-1685, CHARACTERIZATION OF VARIANT DRVT PHE-986,
RP   FUNCTION, TRANSPORTER ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=14672992; DOI=10.1523/jneurosci.23-36-11289.2003;
RA   Lossin C., Rhodes T.H., Desai R.R., Vanoye C.G., Wang D., Carniciu S.,
RA   Devinsky O., George A.L. Jr.;
RT   "Epilepsy-associated dysfunction in the voltage-gated neuronal sodium
RT   channel SCN1A.";
RL   J. Neurosci. 23:11289-11295(2003).
RN   [24]
RP   VARIANTS GLN-542; THR-1034; LEU-1038; THR-1067 AND THR-1955.
RX   PubMed=12610651; DOI=10.1038/sj.mp.4001241;
RA   Weiss L.A., Escayg A., Kearney J.A., Trudeau M., MacDonald B.T., Mori M.,
RA   Reichert J., Buxbaum J.D., Meisler M.H.;
RT   "Sodium channels SCN1A, SCN2A and SCN3A in familial autism.";
RL   Mol. Psychiatry 8:186-194(2003).
RN   [25]
RP   VARIANTS DRVT ASP-78; GLU-177; SER-227; ARG-280; ILE-297; ASN-426;
RP   ARG-1233; ILE-1461; SER-1463; ALA-1668; THR-1780 AND 1812-TRP--LYS-1815
RP   DELINS CYS.
RX   PubMed=12821740; DOI=10.1212/01.wnl.0000069463.41870.2f;
RA   Nabbout R., Gennaro E., Dalla Bernardina B., Dulac O., Madia F.,
RA   Bertini E., Capovilla G., Chiron C., Cristofori G., Elia M., Fontana E.,
RA   Gaggero R., Granata T., Guerrini R., Loi M., La Selva L., Lispi M.L.,
RA   Matricardi A., Romeo A., Tzolas V., Valseriati D., Veggiotti P.,
RA   Vigevano F., Vallee L., Dagna Bricarelli F., Bianchi A., Zara F.;
RT   "Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy.";
RL   Neurology 60:1961-1967(2003).
RN   [26]
RP   VARIANTS DRVT PRO-1326 AND ASP-1881, AND VARIANT INFANTILE SPASMS GLY-1957.
RX   PubMed=14504318; DOI=10.1212/01.wnl.0000086379.71183.78;
RA   Wallace R.H., Hodgson B.L., Grinton B.E., Gardiner R.M., Robinson R.,
RA   Rodriguez-Casero V., Sadleir L., Morgan J., Harkin L.A., Dibbens L.M.,
RA   Yamamoto T., Andermann E., Mulley J.C., Berkovic S.F., Scheffer I.E.;
RT   "Sodium channel alpha1-subunit mutations in severe myoclonic epilepsy of
RT   infancy and infantile spasms.";
RL   Neurology 61:765-769(2003).
RN   [27]
RP   CHARACTERIZATION OF VARIANT GEFSP2 ARG-1204.
RX   PubMed=12535936; DOI=10.1016/s0306-4522(02)00698-x;
RA   Spampanato J., Escayg A., Meisler M.H., Goldin A.L.;
RT   "Generalized epilepsy with febrile seizures plus type 2 mutation W1204R
RT   alters voltage-dependent gating of Na(v)1.1 sodium channels.";
RL   Neuroscience 116:37-48(2003).
RN   [28]
RP   VARIANTS DRVT GLN-101; ARG-190; ILE-934; ALA-944; CYS-946; HIS-946;
RP   PRO-1355; MET-1559 DEL; SER-1692; CYS-1694; PHE-1766 DEL AND CYS-1781.
RX   PubMed=14738421; DOI=10.1111/j.0013-9580.2004.15103.x;
RA   Fukuma G., Oguni H., Shirasaka Y., Watanabe K., Miyajima T., Yasumoto S.,
RA   Ohfu M., Inoue T., Watanachai A., Kira R., Matsuo M., Muranaka H.,
RA   Sofue F., Zhang B., Kaneko S., Mitsudome A., Hirose S.;
RT   "Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A
RT   in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI
RT   (SMEB).";
RL   Epilepsia 45:140-148(2004).
RN   [29]
RP   VARIANT GEFSP2 TYR-1866, CHARACTERIZATION OF VARIANT GEFSP2 TYR-1866, AND
RP   INTERACTION WITH SCN1B.
RX   PubMed=15525788; DOI=10.1523/jneurosci.2034-04.2004;
RA   Spampanato J., Kearney J.A., de Haan G., McEwen D.P., Escayg A., Aradi I.,
RA   MacDonald B.T., Levin S.I., Soltesz I., Benna P., Montalenti E., Isom L.L.,
RA   Goldin A.L., Meisler M.H.;
RT   "A novel epilepsy mutation in the sodium channel SCN1A identifies a
RT   cytoplasmic domain for beta subunit interaction.";
RL   J. Neurosci. 24:10022-10034(2004).
RN   [30]
RP   VARIANT DRVT ASN-252.
RX   PubMed=15087100; DOI=10.1016/j.pediatrneurol.2003.10.012;
RA   Ceulemans B.P.G.M., Claes L.R.F., Lagae L.G.;
RT   "Clinical correlations of mutations in the SCN1A gene: from febrile
RT   seizures to severe myoclonic epilepsy in infancy.";
RL   Pediatr. Neurol. 30:236-243(2004).
RN   [31]
RP   VARIANT DRVT ASN-1713, AND VARIANT THR-1067.
RX   PubMed=16122630; DOI=10.1016/j.braindev.2004.11.005;
RA   Kimura K., Sugawara T., Mazaki-Miyazaki E., Hoshino K., Nomura Y.,
RA   Tateno A., Hachimori K., Yamakawa K., Segawa M.;
RT   "A missense mutation in SCN1A in brothers with severe myoclonic epilepsy in
RT   infancy (SMEI) inherited from a father with febrile seizures.";
RL   Brain Dev. 27:424-430(2005).
RN   [32]
RP   VARIANT GEFSP2 LEU-1857.
RX   PubMed=15715999; DOI=10.1016/j.eplepsyres.2004.11.005;
RA   Nagao Y., Mazaki-Miyazaki E., Okamura N., Takagi M., Igarashi T.,
RA   Yamakawa K.;
RT   "A family of generalized epilepsy with febrile seizures plus type 2-a new
RT   missense mutation of SCN1A found in the pedigree of several patients with
RT   complex febrile seizures.";
RL   Epilepsy Res. 63:151-156(2005).
RN   [33]
RP   VARIANTS ICEGTC SER-808 AND ILE-1011, AND CHARACTERIZATION OF VARIANTS
RP   ICEGTC SER-808; ARG-979; ALA-983; ILE-1011; PHE-1611; SER-1632; ILE-1709
RP   AND LEU-1808.
RX   PubMed=16210358; DOI=10.1113/jphysiol.2005.094326;
RA   Rhodes T.H., Vanoye C.G., Ohmori I., Ogiwara I., Yamakawa K.,
RA   George A.L. Jr.;
RT   "Sodium channel dysfunction in intractable childhood epilepsy with
RT   generalized tonic-clonic seizures.";
RL   J. Physiol. (Lond.) 569:433-445(2005).
RN   [34]
RP   VARIANT FHM3 LYS-1489.
RX   PubMed=16054936; DOI=10.1016/s0140-6736(05)66786-4;
RA   Dichgans M., Freilinger T., Eckstein G., Babini E., Lorenz-Depiereux B.,
RA   Biskup S., Ferrari M.D., Herzog J., van den Maagdenberg A.M.J.M., Pusch M.,
RA   Strom T.M.;
RT   "Mutation in the neuronal voltage-gated sodium channel SCN1A in familial
RT   hemiplegic migraine.";
RL   Lancet 366:371-377(2005).
RN   [35]
RP   VARIANT DRVT SER-946.
RX   PubMed=15944908; DOI=10.1055/s-2005-865607;
RA   Ebach K., Joos H., Doose H., Stephani U., Kurlemann G., Fiedler B.,
RA   Hahn A., Hauser E., Hundt K., Holthausen H., Mueller U., Neubauer B.A.;
RT   "SCN1A mutation analysis in myoclonic astatic epilepsy and severe
RT   idiopathic generalized epilepsy of infancy with generalized tonic-clonic
RT   seizures.";
RL   Neuropediatrics 36:210-213(2005).
RN   [36]
RP   VARIANT FEB3A THR-145, AND CHARACTERIZATION OF VARIANT FEB3A THR-145.
RX   PubMed=16326807; DOI=10.1073/pnas.0506818102;
RA   Mantegazza M., Gambardella A., Rusconi R., Schiavon E., Annesi F.,
RA   Cassulini R.R., Labate A., Carrideo S., Chifari R., Canevini M.P.,
RA   Canger R., Franceschetti S., Annesi G., Wanke E., Quattrone A.;
RT   "Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function
RT   mutation associated with familial simple febrile seizures.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:18177-18182(2005).
RN   [37]
RP   VARIANT GEFSP2 GLY-1742.
RX   PubMed=15694566; DOI=10.1016/j.seizure.2004.12.007;
RA   Pineda-Trujillo N., Carrizosa J., Cornejo W., Arias W., Franco C.,
RA   Cabrera D., Bedoya G., Ruiz-Linares A.;
RT   "A novel SCN1A mutation associated with severe GEFS+ in a large South
RT   American pedigree.";
RL   Seizure 14:123-128(2005).
RN   [38]
RP   VARIANT DRVT PRO-1393.
RX   PubMed=17129991; DOI=10.1080/08035250600778628;
RA   Stefanaki E., Aggelakou V., Orfanou M., Kokori E., Boutoufianakis S.;
RT   "Epilepsy with a de novo missense mutation in the sodium channel a1
RT   subunit: a case report.";
RL   Acta Paediatr. 95:1703-1706(2006).
RN   [39]
RP   VARIANTS DRVT ASP-78; PRO-162; ASN-194; LYS-217; SER-227; ARG-280; LEU-383;
RP   CYS-393; SER-393; ASN-426; ARG-812; LYS-846; PRO-942; ARG-1233; GLN-1245;
RP   CYS-1422; ARG-1426; LEU-1451; SER-1463; SER-1475; ALA-1668; ARG-1714;
RP   GLU-1762; PHE-1773 AND THR-1780.
RX   PubMed=17054684; DOI=10.1111/j.1528-1167.2006.00641.x;
RA   Mancardi M.M., Striano P., Gennaro E., Madia F., Paravidino R.,
RA   Scapolan S., Dalla Bernardina B., Bertini E., Bianchi A., Capovilla G.,
RA   Darra F., Elia M., Freri E., Gobbi G., Granata T., Guerrini R.,
RA   Pantaleoni C., Parmeggiani A., Romeo A., Santucci M., Vecchi M.,
RA   Veggiotti P., Vigevano F., Pistorio A., Gaggero R., Zara F.;
RT   "Familial occurrence of febrile seizures and epilepsy in severe myoclonic
RT   epilepsy of infancy (SMEI) patients with SCN1A mutations.";
RL   Epilepsia 47:1629-1635(2006).
RN   [40]
RP   CHARACTERIZATION OF VARIANTS DRVT GLU-177; SER-227; HIS-393; ASN-426;
RP   GLN-939; ARG-959; PHE-1289 DEL AND ILE-1909.
RX   PubMed=17054685; DOI=10.1111/j.1528-1167.2006.00643.x;
RA   Ohmori I., Kahlig K.M., Rhodes T.H., Wang D.W., George A.L. Jr.;
RT   "Nonfunctional SCN1A is common in severe myoclonic epilepsy of infancy.";
RL   Epilepsia 47:1636-1642(2006).
RN   [41]
RP   VARIANT GEFSP2 CYS-859, AND CHARACTERIZATION OF VARIANT GEFSP2 CYS-859.
RX   PubMed=16525050; DOI=10.1523/jneurosci.2977-05.2006;
RA   Barela A.J., Waddy S.P., Lickfett J.G., Hunter J., Anido A., Helmers S.L.,
RA   Goldin A.L., Escayg A.;
RT   "An epilepsy mutation in the sodium channel SCN1A that decreases channel
RT   excitability.";
RL   J. Neurosci. 26:2714-2723(2006).
RN   [42]
RP   VARIANTS DRVT LEU-403; ASN-413; HIS-946; ASP-1238; GLY-1396 AND GLN-1645.
RX   PubMed=16713920; DOI=10.1016/s1474-4422(06)70446-x;
RA   Berkovic S.F., Harkin L., McMahon J.M., Pelekanos J.T., Zuberi S.M.,
RA   Wirrell E.C., Gill D.S., Iona X., Mulley J.C., Scheffer I.E.;
RT   "De-novo mutations of the sodium channel gene SCN1A in alleged vaccine
RT   encephalopathy: a retrospective study.";
RL   Lancet Neurol. 5:488-492(2006).
RN   [43]
RP   VARIANT DRVT THR-1231.
RX   PubMed=16458823; DOI=10.1016/j.pediatrneurol.2005.07.009;
RA   Kearney J.A., Wiste A.K., Stephani U., Trudeau M.M., Siegel A.,
RA   Ramachandrannair R., Elterman R.D., Muhle H., Reinsdorf J., Shields W.D.,
RA   Meisler M.H., Escayg A.;
RT   "Recurrent de novo mutations of SCN1A in severe myoclonic epilepsy of
RT   infancy.";
RL   Pediatr. Neurol. 34:116-120(2006).
RN   [44]
RP   VARIANTS CYS-393; PRO-395; GLU-422; GLY-626; VAL-1480; SER-1543; GLN-1636
RP   AND HIS-1657, VARIANTS DRVT HIS-79; CYS-84; TRP-101; ARG-199; THR-239;
RP   LEU-403; ASN-413; GLY-674; PRO-783; GLU-944; LEU-945; GLU-950; ASP-1238;
RP   MET-1390; GLY-1396; PRO-1441; VAL-1545; CYS-1596; GLN-1645; VAL-1707;
RP   ARG-1721 AND THR-1922, VARIANT GEFSP2 VAL-973, AND VARIANT DEE6B MET-226.
RX   PubMed=17347258; DOI=10.1093/brain/awm002;
RG   The infantile epileptic encephalopathy referral consortium;
RA   Harkin L.A., McMahon J.M., Iona X., Dibbens L., Pelekanos J.T.,
RA   Zuberi S.M., Sadleir L.G., Andermann E., Gill D., Farrell K., Connolly M.,
RA   Stanley T., Harbord M., Andermann F., Wang J., Batish S.D., Jones J.G.,
RA   Seltzer W.K., Gardner A., Sutherland G., Berkovic S.F., Mulley J.C.,
RA   Scheffer I.E.;
RT   "The spectrum of SCN1A-related infantile epileptic encephalopathies.";
RL   Brain 130:843-852(2007).
RN   [45]
RP   VARIANTS DRVT GLN-101; ILE-322; GLY-356; THR-358; CYS-393; HIS-393;
RP   LEU-957; TYR-1414; TRP-1470; ARG-1588; TYR-1608; MET-1630; ARG-1658;
RP   ARG-1716; VAL-1783 AND LYS-1787, AND VARIANTS GEFSP2 PRO-74; ARG-1204 AND
RP   SER-1687.
RX   PubMed=17561957; DOI=10.1111/j.1528-1167.2007.01122.x;
RA   Marini C., Mei D., Temudo T., Ferrari A.R., Buti D., Dravet C., Dias A.I.,
RA   Moreira A., Calado E., Seri S., Neville B., Narbona J., Reid E.,
RA   Michelucci R., Sicca F., Cross H.J., Guerrini R.;
RT   "Idiopathic epilepsies with seizures precipitated by fever and SCN1A
RT   abnormalities.";
RL   Epilepsia 48:1678-1685(2007).
RN   [46]
RP   VARIANT GEFSP2 ILE-1366, AND VARIANT ICEGTC ILE-1366.
RX   PubMed=17507202; DOI=10.1016/j.eplepsyres.2007.03.018;
RA   Osaka H., Ogiwara I., Mazaki E., Okamura N., Yamashita S., Iai M.,
RA   Yamada M., Kurosawa K., Iwamoto H., Yasui-Furukori N., Kaneko S.,
RA   Fujiwara T., Inoue Y., Yamakawa K.;
RT   "Patients with a sodium channel alpha 1 gene mutation show wide phenotypic
RT   variation.";
RL   Epilepsy Res. 75:46-51(2007).
RN   [47]
RP   VARIANT FHM3 GLN-1649.
RX   PubMed=17397047; DOI=10.1002/humu.9486;
RA   Vanmolkot K.R., Babini E., de Vries B., Stam A.H., Freilinger T.,
RA   Terwindt G.M., Norris L., Haan J., Frants R.R., Ramadan N.M., Ferrari M.D.,
RA   Pusch M., van den Maagdenberg A.M., Dichgans M.;
RT   "The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with
RT   familial hemiplegic migraine: genetic and functional studies. Mutation in
RT   brief #957. Online.";
RL   Hum. Mutat. 28:522-522(2007).
RN   [48]
RP   CHARACTERIZATION OF VARIANT GEFSP2 THR-1852, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH SCN1B.
RX   PubMed=17928445; DOI=10.1523/jneurosci.3515-07.2007;
RA   Rusconi R., Scalmani P., Cassulini R.R., Giunti G., Gambardella A.,
RA   Franceschetti S., Annesi G., Wanke E., Mantegazza M.;
RT   "Modulatory proteins can rescue a trafficking defective epileptogenic
RT   Nav1.1 Na+ channel mutant.";
RL   J. Neurosci. 27:11037-11046(2007).
RN   [49]
RP   VARIANT PHE-790, AND POSSIBLE INVOLVEMENT IN PANAYIOTOPOULOS SYNDROME.
RX   PubMed=17679682; DOI=10.1212/01.wnl.0000266666.10404.53;
RA   Grosso S., Orrico A., Galli L., Di Bartolo R., Sorrentino V., Balestri P.;
RT   "SCN1A mutation associated with atypical Panayiotopoulos syndrome.";
RL   Neurology 69:609-611(2007).
RN   [50]
RP   VARIANT FOCAL EPILEPSY PHE-1771.
RX   PubMed=18330841; DOI=10.1055/s-2008-1062703;
RA   Okumura A., Kurahashi H., Hirose S., Okawa N., Watanabe K.;
RT   "Focal epilepsy resulting from a de novo SCN1A mutation.";
RL   Neuropediatrics 38:253-256(2007).
RN   [51]
RP   VARIANT FHM3 SER-1174.
RX   PubMed=18021921; DOI=10.1016/j.pediatrneurol.2007.06.016;
RA   Gargus J.J., Tournay A.;
RT   "Novel mutation confirms seizure locus SCN1A is also familial hemiplegic
RT   migraine locus FHM3.";
RL   Pediatr. Neurol. 37:407-410(2007).
RN   [52]
RP   VARIANT GEFSP2 MET-978.
RX   PubMed=17927801; DOI=10.1111/j.1600-0404.2007.00941.x;
RA   Selmer K.K., Egeland T., Solaas M.H., Nakken K.O., Kjeldsen M.J.,
RA   Friis M.L., Brandal K., Corey L.A., Undlien D.E.;
RT   "Genetic screening of Scandinavian families with febrile seizures and
RT   epilepsy or GEFS+.";
RL   Acta Neurol. Scand. 117:289-292(2008).
RN   [53]
RP   VARIANTS DRVT SER-118; GLU-366; PRO-1207; MET-1335; SER-1358 AND CYS-1462,
RP   VARIANT GEFSP2 GLN-377, AND VARIANT GLY-1928.
RX   PubMed=18413471; DOI=10.1001/archneur.65.4.489;
RA   Zucca C., Redaelli F., Epifanio R., Zanotta N., Romeo A., Lodi M.,
RA   Veggiotti P., Airoldi G., Panzeri C., Romaniello R., De Polo G.,
RA   Bonanni P., Cardinali S., Baschirotto C., Martorell L., Borgatti R.,
RA   Bresolin N., Bassi M.T.;
RT   "Cryptogenic epileptic syndromes related to SCN1A: twelve novel mutations
RT   identified.";
RL   Arch. Neurol. 65:489-494(2008).
RN   [54]
RP   VARIANT GEFSP2 THR-1867.
RX   PubMed=18251839; DOI=10.1111/j.1528-1167.2007.01439_2.x;
RA   Hindocha N., Nashef L., Elmslie F., Birch R., Zuberi S., Al-Chalabi A.,
RA   Crotti L., Schwartz P.J., Makoff A.;
RT   "Two cases of sudden unexpected death in epilepsy in a GEFS+ family with an
RT   SCN1A mutation.";
RL   Epilepsia 49:360-365(2008).
RN   [55]
RP   VARIANT CYS-1575.
RX   PubMed=18031552; DOI=10.1111/j.1528-1167.2007.01411.x;
RA   Ohmori I., Ouchida M., Kobayashi K., Jitsumori Y., Inoue T., Shimizu K.,
RA   Matsui H., Ohtsuka Y., Maegaki Y.;
RT   "Rasmussen encephalitis associated with SCN 1 A mutation.";
RL   Epilepsia 49:521-526(2008).
RN   [56]
RP   VARIANT GEFSP2 HIS-935.
RX   PubMed=18566737; DOI=10.1007/s10038-008-0306-y;
RA   Sun H., Zhang Y., Liang J., Liu X., Ma X., Wu H., Xu K., Qin J., Qi Y.,
RA   Wu X.;
RT   "SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with
RT   generalized epilepsy with febrile seizures plus.";
RL   J. Hum. Genet. 53:769-774(2008).
RN   [57]
RP   VARIANT DRVT CYS-280.
RX   PubMed=18639757; DOI=10.1016/j.pediatrneurol.2008.04.003;
RA   Miyama S., Goto T., Inoue Y., Yamakawa K.;
RT   "Monozygotic twins with severe myoclonic epilepsy in infancy discordant for
RT   clinical features.";
RL   Pediatr. Neurol. 39:120-122(2008).
RN   [58]
RP   VARIANT THR-1067.
RX   PubMed=19694741; DOI=10.1111/j.1365-2125.2009.03437.x;
RA   Lakhan R., Kumari R., Misra U.K., Kalita J., Pradhan S., Mittal B.;
RT   "Differential role of sodium channels SCN1A and SCN2A gene polymorphisms
RT   with epilepsy and multiple drug resistance in the north Indian
RT   population.";
RL   Br. J. Clin. Pharmacol. 68:214-220(2009).
RN   [59]
RP   VARIANT DRVT LYS-1503.
RX   PubMed=19783390; DOI=10.1016/j.braindev.2009.08.009;
RA   Shi X., Yasumoto S., Nakagawa E., Fukasawa T., Uchiya S., Hirose S.;
RT   "Missense mutation of the sodium channel gene SCN2A causes Dravet
RT   syndrome.";
RL   Brain Dev. 31:758-762(2009).
RN   [60]
RP   VARIANTS GLN-542 AND PHE-790, VARIANT FEB3A ASP-1308, VARIANT DRVT
RP   CYS-1648, VARIANTS GEFSP2 THR-899; ILE-976; ASN-1249 AND MET-1250, AND
RP   POSSIBLE INVOLVEMENT IN PANAYIOTOPOULOS SYNDROME.
RX   PubMed=19522081; DOI=10.1111/j.1399-0004.2009.01155.x;
RA   Orrico A., Galli L., Grosso S., Buoni S., Pianigiani R., Balestri P.,
RA   Sorrentino V.;
RT   "Mutational analysis of the SCN1A, SCN1B and GABRG2 genes in 150 Italian
RT   patients with idiopathic childhood epilepsies.";
RL   Clin. Genet. 75:579-581(2009).
RN   [61]
RP   VARIANT GEFSP2 LEU-218, AND POSSIBLE INVOLVEMENT IN PANAYIOTOPOULOS
RP   SYNDROME.
RX   PubMed=19339291; DOI=10.1177/0883073808324537;
RA   Livingston J.H., Cross J.H., Mclellan A., Birch R., Zuberi S.M.;
RT   "A novel inherited mutation in the voltage sensor region of SCN1A is
RT   associated with Panayiotopoulos syndrome in siblings and generalized
RT   epilepsy with febrile seizures plus.";
RL   J. Child Neurol. 24:503-508(2009).
RN   [62]
RP   VARIANTS GLN-542; HIS-604; THR-924; ILE-1079; THR-1109; ASP-1308; CYS-1575
RP   AND GLY-1928, AND VARIANTS DRVT VAL-58; PHE-61; HIS-79; GLN-101; TRP-101;
RP   ASN-124; ARG-171; VAL-175; LYS-191; TYR-191; GLY-194; GLU-223; SER-227;
RP   SER-232; TYR-243; ARG-277; LEU-281; SER-281; ILE-322; PHE-340; ASP-343;
RP   ARG-345; ASP-355; ILE-357; GLN-378; CYS-393; MET-400 DEL; CYS-426; PHE-525;
RP   GLY-626; ARG-843; CYS-859; LYS-875; LEU-896; PHE-927; CYS-931; ILE-934;
RP   PRO-939; ASN-943; SER-949; TYR-949; LYS-973; PRO-986; GLY-998; LYS-1068;
RP   GLY-1239; TYR-1239; ASP-1255; VAL-1275; SER-1284; PHE-1289 DEL; SER-1316;
RP   PRO-1328; LYS-1367; SER-1391; GLY-1416; ILE-1431; MET-1437; PHE-1473 DEL;
RP   ILE-1483 DEL; GLY-1484; ILE-1538; ALA-1544; LYS-1561; GLU-1579; GLU-1586;
RP   CYS-1596; LEU-1596; ILE-1612; GLY-1639; HIS-1648; ARG-1658; MET-1658;
RP   LYS-1664; ARG-1675; PHE-1677; LYS-1714; CYS-1725; ASN-1771; THR-1780;
RP   HIS-1781; MET-1782; SER-1782; THR-1783; VAL-1783; LYS-1788; ILE-1808;
RP   SER-1812; 1813-GLU--PHE-1815 DEL AND PHE-1835.
RX   PubMed=18930999; DOI=10.1136/jmg.2008.062323;
RA   Depienne C., Trouillard O., Saint-Martin C., Gourfinkel-An I.,
RA   Bouteiller D., Carpentier W., Keren B., Abert B., Gautier A., Baulac S.,
RA   Arzimanoglou A., Cazeneuve C., Nabbout R., LeGuern E.;
RT   "Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis
RT   of 333 patients.";
RL   J. Med. Genet. 46:183-191(2009).
RN   [63]
RP   VARIANTS FHM3 HIS-1489 AND LEU-1499.
RX   PubMed=19332696; DOI=10.1212/01.wnl.0000345393.53132.8c;
RA   Vahedi K., Depienne C., Le Fort D., Riant F., Chaine P., Trouillard O.,
RA   Gaudric A., Morris M.A., LeGuern E., Tournier-Lasserve E., Bousser M.-G.;
RT   "Elicited repetitive daily blindness: a new phenotype associated with
RT   hemiplegic migraine and SCN1A mutations.";
RL   Neurology 72:1178-1183(2009).
RN   [64]
RP   VARIANT GEFSP2 HIS-388.
RX   PubMed=19464195; DOI=10.1016/j.seizure.2009.04.009;
RA   Mahoney K., Moore S.J., Buckley D., Alam M., Parfrey P., Penney S.,
RA   Merner N., Hodgkinson K., Young T.L.;
RT   "Variable neurologic phenotype in a GEFS+ family with a novel mutation in
RT   SCN1A.";
RL   Seizure 18:492-497(2009).
RN   [65]
RP   VARIANT THR-1067.
RX   PubMed=20682179; DOI=10.1016/j.arcmed.2010.04.007;
RA   Ebrahimi A., Houshmand M., Tonekaboni S.H., Fallah Mahboob Passand M.S.,
RA   Zainali S., Moghadasi M.;
RT   "Two novel mutations in SCN1A gene in Iranian patients with epilepsy.";
RL   Arch. Med. Res. 41:207-214(2010).
RN   [66]
RP   VARIANTS GEFSP2 HIS-946 AND LEU-1765, AND CHARACTERIZATION OF VARIANTS
RP   GEFSP2 HIS-946 AND LEU-1765.
RX   PubMed=20550552; DOI=10.1111/j.1528-1167.2010.02645.x;
RA   Liao W.P., Shi Y.W., Long Y.S., Zeng Y., Li T., Yu M.J., Su T., Deng P.,
RA   Lei Z.G., Xu S.J., Deng W.Y., Liu X.R., Sun W.W., Yi Y.H., Xu Z.C.,
RA   Duan S.;
RT   "Partial epilepsy with antecedent febrile seizures and seizure aggravation
RT   by antiepileptic drugs: associated with loss of function of Na(v) 1.1.";
RL   Epilepsia 51:1669-1678(2010).
RN   [67]
RP   VARIANTS DRVT ILE-1612 AND GLY-1756.
RX   PubMed=20452746; DOI=10.1016/j.eplepsyres.2010.04.003;
RA   Herini E.S., Gunadi Harahap I.S., Yusoff S., Morikawa S., Patria S.Y.,
RA   Nishimura N., Sunartini Sutaryo S., Takada S., Matsuo M., Nishio H.;
RT   "Generalized epilepsy with febrile seizures plus (GEFS+) spectrum: clinical
RT   manifestations and SCN1A mutations in Indonesian patients.";
RL   Epilepsy Res. 90:132-139(2010).
RN   [68]
RP   VARIANT GLU-1637.
RX   PubMed=20392657; DOI=10.1016/j.ejpn.2010.03.002;
RA   Nishri D., Blumkin L., Lev D., Leshinsky-Silver E., Abu-Rashid M.,
RA   Birch R., Zuberi S.M., Lerman-Sagie T.;
RT   "Hepatic coma culminating in severe brain damage in a child with a SCN1A
RT   mutation.";
RL   Eur. J. Paediatr. Neurol. 14:456-459(2010).
RN   [69]
RP   VARIANTS DRVT GLN-862 AND LYS-954.
RX   PubMed=20110217; DOI=10.1177/0883073809357241;
RA   Arlier Z., Bayri Y., Kolb L.E., Erturk O., Ozturk A.K., Bayrakli F.,
RA   Bilguvar K., Moliterno J.A., Dervent A., Demirbilek V., Yalcinkaya C.,
RA   Korkmaz B., Tuysuz B., Gunel M.;
RT   "Four novel SCN1A mutations in Turkish patients with severe myoclonic
RT   epilepsy of infancy (SMEI).";
RL   J. Child Neurol. 25:1265-1268(2010).
RN   [70]
RP   VARIANT GEFSP2 THR-27, VARIANTS DRVT LEU-63; VAL-239 AND ARG-1433, AND
RP   VARIANT ASP-1308.
RX   PubMed=20729507; DOI=10.1177/0883073810365737;
RA   Nicita F., Spalice A., Papetti L., Ursitti F., Parisi P., Gennaro E.,
RA   Zara F., Iannetti P.;
RT   "Genotype-phenotype correlations in a group of 15 SCN1A-mutated Italian
RT   patients with GEFS+ spectrum (seizures plus, classical and borderline
RT   severe myoclonic epilepsy of infancy).";
RL   J. Child Neurol. 25:1369-1376(2010).
RN   [71]
RP   VARIANTS DRVT SER-90; THR-91; TRP-101; GLN-101; THR-239; ARG-259; HIS-393;
RP   TYR-939; GLY-952; LYS-1210; PRO-1260; PRO-1287; MET-1335; MET-1390;
RP   GLU-1433; GLU-1586 AND THR-1783.
RX   PubMed=20431604; DOI=10.1038/jhg.2010.39;
RA   Sun H., Zhang Y., Liu X., Ma X., Yang Z., Qin J., Jiang Y., Qi Y., Wu X.;
RT   "Analysis of SCN1A mutation and parental origin in patients with Dravet
RT   syndrome.";
RL   J. Hum. Genet. 55:421-427(2010).
RN   [72]
RP   VARIANTS DRVT CYS-84; GLN-101; LYS-171; THR-175; ASN-194; SER-227; PHE-406;
RP   ASN-413; PRO-783; GLU-944; LEU-945; HIS-946; GLU-950; GLY-1396; LYS-1450;
RP   VAL-1545; GLN-1645; ARG-1726 AND THR-1783, AND VARIANTS HIS-604; GLN-1636
RP   AND HIS-1657.
RX   PubMed=19589774; DOI=10.1136/jmg.2008.065912;
RA   Heron S.E., Scheffer I.E., Iona X., Zuberi S.M., Birch R., McMahon J.M.,
RA   Bruce C.M., Berkovic S.F., Mulley J.C.;
RT   "De novo SCN1A mutations in Dravet syndrome and related epileptic
RT   encephalopathies are largely of paternal origin.";
RL   J. Med. Genet. 47:137-141(2010).
RN   [73]
RP   VARIANTS DRVT ASN-124; TYR-191; LYS-875; LYS-1367; SER-1514; HIS-1648;
RP   MET-1658; LYS-1664 AND MET-1782.
RX   PubMed=20522430; DOI=10.1136/jmg.2009.074328;
RA   Depienne C., Trouillard O., Gourfinkel-An I., Saint-Martin C.,
RA   Bouteiller D., Graber D., Barthez-Carpentier M.A., Gautier A.,
RA   Villeneuve N., Dravet C., Livet M.O., Rivier-Ringenbach C., Adam C.,
RA   Dupont S., Baulac S., Heron D., Nabbout R., Leguern E.;
RT   "Mechanisms for variable expressivity of inherited SCN1A mutations causing
RT   Dravet syndrome.";
RL   J. Med. Genet. 47:404-410(2010).
RN   [74]
RP   VARIANT GEFSP2 LYS-1795.
RX   PubMed=20600615; DOI=10.1016/j.neulet.2010.06.040;
RA   Li N., Zhang J., Guo J.F., Yan X.X., Xia K., Tang B.S.;
RT   "Novel mutation of SCN1A in familial generalized epilepsy with febrile
RT   seizures plus.";
RL   Neurosci. Lett. 480:211-214(2010).
RN   [75]
RP   VARIANTS DRVT ILE-1612 AND GLY-1756.
RX   PubMed=19563458; DOI=10.1111/j.1442-200x.2009.02916.x;
RA   Herini E.S., Gunadi H., van Kempen M.J., Yusoff S., Sutaryo S.,
RA   Patria S.Y., Matsuo M., Lindhout D., Nishio H.;
RT   "Novel SCN1A mutations in Indonesian patients with severe myoclonic
RT   epilepsy in infancy.";
RL   Pediatr. Int. 52:234-239(2010).
RN   [76]
RP   VARIANT GEFSP2 PHE-1309.
RX   PubMed=20117752; DOI=10.1016/j.pediatrneurol.2009.09.007;
RA   Dimova P.S., Yordanova I., Bojinova V., Jordanova A., Kremenski I.;
RT   "Generalized epilepsy with febrile seizures plus: novel SCN1A mutation.";
RL   Pediatr. Neurol. 42:137-140(2010).
RN   [77]
RP   VARIANTS DRVT LYS-226; HIS-931; ALA-1266; HIS-1462; THR-1523; THR-1638 AND
RP   GLU-1880.
RX   PubMed=21719429; DOI=10.1093/brain/awr129;
RA   Catarino C.B., Liu J.Y., Liagkouras I., Gibbons V.S., Labrum R.W.,
RA   Ellis R., Woodward C., Davis M.B., Smith S.J., Cross J.H., Appleton R.E.,
RA   Yendle S.C., McMahon J.M., Bellows S.T., Jacques T.S., Zuberi S.M.,
RA   Koepp M.J., Martinian L., Scheffer I.E., Thom M., Sisodiya S.M.;
RT   "Dravet syndrome as epileptic encephalopathy: evidence from long-term
RT   course and neuropathology.";
RL   Brain 134:2982-3010(2011).
RN   [78]
RP   VARIANT DRVT GLU-1669.
RX   PubMed=21555645; DOI=10.1001/archneurol.2011.98;
RA   Freilich E.R., Jones J.M., Gaillard W.D., Conry J.A., Tsuchida T.N.,
RA   Reyes C., Dib-Hajj S., Waxman S.G., Meisler M.H., Pearl P.L.;
RT   "Novel SCN1A mutation in a proband with malignant migrating partial
RT   seizures of infancy.";
RL   Arch. Neurol. 68:665-671(2011).
RN   [79]
RP   VARIANT GEFSP2 HIS-859, VARIANT DRVT GLY-865, CHARACTERIZATION OF VARIANT
RP   GEFSP2 HIS-859, AND CHARACTERIZATION OF VARIANTS DRVT GLY-865; CYS-946 AND
RP   HIS-946.
RX   PubMed=21864321; DOI=10.1111/j.1460-9568.2011.07826.x;
RA   Volkers L., Kahlig K.M., Verbeek N.E., Das J.H., van Kempen M.J.,
RA   Stroink H., Augustijn P., van Nieuwenhuizen O., Lindhout D.,
RA   George A.L. Jr., Koeleman B.P., Rook M.B.;
RT   "Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or
RT   Dravet syndrome.";
RL   Eur. J. Neurosci. 34:1268-1275(2011).
RN   [80]
RP   VARIANTS DRVT PHE-17 DEL; THR-68; ASN-79; CYS-84; PRO-98; GLN-101; TRP-101;
RP   ARG-108; ASP-127; ARG-199; SER-227; THR-227; SER-232; ARG-233; VAL-342;
RP   ASP-343; TRP-351; SER-359; ARG-363; ARG-384; CYS-393; HIS-393; VAL-400;
RP   VAL-403; PHE-406; GLY-626; ASP-762; THR-785; ILE-812; ARG-842;
RP   854-GLY-LEU-855 DEL; CYS-859; GLN-862; PRO-890; CYS-932; PRO-933; CYS-946;
RP   HIS-946; ARG-950; LYS-954; LYS-956; LEU-957; ILE-976; VAL-979; ARG-993;
RP   999-ASN-LEU-1000 DELINS LEU-ILE-SER; LYS-1208; LYS-1221; PHE-1230;
RP   ASP-1238; ALA-1266; ASN-1288; VAL-1320; PRO-1326; GLY-1350; ARG-1358;
RP   PRO-1370; HIS-1378; THR-1378; ILE-1394; TYR-1396; SER-1417; PHE-1423;
RP   ALA-1429 DEL; VAL-1433; LYS-1450; SER-1451; LYS-1454; HIS-1462; LYS-1476;
RP   LYS-1503; GLY-1544; GLU-1586; ARG-1588; HIS-1592; PRO-1592; SER-1605;
RP   GLU-1637; THR-1638; CYS-1648; GLU-1653; PRO-1660; PRO-1667; LEU-1668;
RP   ILE-1672; THR-1673; THR-1683; ASP-1684; TRP-1688; ARG-1714; ASN-1763;
RP   ASN-1770; PHE-1770; THR-1770; THR-1780; VAL-1783; LYS-1787; PRO-1832;
RP   LYS-1852; LEU-1855; GLU-1880; THR-1909 DEL AND ARG-1927 DELINS ILE-ILE-GLN,
RP   VARIANTS GEFSP2 LEU-218; ILE-254; GLY-291; THR-960; VAL-973; SER-1204;
RP   PHE-1230; ASP-1414; HIS-1596; LEU-1739 AND THR-1867, AND VARIANTS ASN-45;
RP   VAL-333; ASN-382; HIS-604; ILE-699; THR-924; HIS-931; GLU-1006; ILE-1079;
RP   THR-1109; ASP-1308; ASP-1326; MET-1483 AND PHE-1683.
RX   PubMed=21248271; DOI=10.1212/wnl.0b013e31820c309b;
RA   Zuberi S.M., Brunklaus A., Birch R., Reavey E., Duncan J., Forbes G.H.;
RT   "Genotype-phenotype associations in SCN1A-related epilepsies.";
RL   Neurology 76:594-600(2011).
RN   [81]
RP   VARIANT DRVT GLY-862.
RX   PubMed=21753172; DOI=10.1212/wnl.0b013e318227046d;
RA   Carranza Rojo D., Hamiwka L., McMahon J.M., Dibbens L.M., Arsov T.,
RA   Suls A., Stoedberg T., Kelley K., Wirrell E., Appleton B., Mackay M.,
RA   Freeman J.L., Yendle S.C., Berkovic S.F., Bienvenu T., De Jonghe P.,
RA   Thorburn D.R., Mulley J.C., Mefford H.C., Scheffer I.E.;
RT   "De novo SCN1A mutations in migrating partial seizures of infancy.";
RL   Neurology 77:380-383(2011).
RN   [82]
RP   VARIANTS DRVT VAL-1339 AND LEU-1630.
RX   PubMed=22092154; DOI=10.1111/j.1528-1167.2011.03311.x;
RA   Okumura A., Uematsu M., Imataka G., Tanaka M., Okanishi T., Kubota T.,
RA   Sudo A., Tohyama J., Tsuji M., Ohmori I., Naiki M., Hiraiwa-Sofue A.,
RA   Sato H., Saitoh S., Shimizu T.;
RT   "Acute encephalopathy in children with Dravet syndrome.";
RL   Epilepsia 53:79-86(2012).
RN   [83]
RP   VARIANTS LEU-982; CYS-1575 AND LEU-1977.
RX   PubMed=22309220; DOI=10.1111/j.1528-1167.2011.03402.x;
RA   Saitoh M., Shinohara M., Hoshino H., Kubota M., Amemiya K., Takanashi J.L.,
RA   Hwang S.K., Hirose S., Mizuguchi M.;
RT   "Mutations of the SCN1A gene in acute encephalopathy.";
RL   Epilepsia 53:558-564(2012).
RN   [84]
RP   VARIANTS DRVT VAL-289; ARG-379 AND HIS-393.
RX   PubMed=22612257; DOI=10.1111/j.1528-1167.2012.03516.x;
RA   Lemke J.R., Riesch E., Scheurenbrand T., Schubach M., Wilhelm C.,
RA   Steiner I., Hansen J., Courage C., Gallati S., Buerki S., Strozzi S.,
RA   Simonetti B.G., Grunt S., Steinlin M., Alber M., Wolff M., Klopstock T.,
RA   Prott E.C., Lorenz R., Spaich C., Rona S., Lakshminarasimhan M., Kroell J.,
RA   Dorn T., Kraemer G., Synofzik M., Becker F., Weber Y.G., Lerche H.,
RA   Boehm D., Biskup S.;
RT   "Targeted next generation sequencing as a diagnostic tool in epileptic
RT   disorders.";
RL   Epilepsia 53:1387-1398(2012).
RN   [85]
RP   VARIANTS DRVT CYS-84; GLN-101; TRP-101; ILE-105; ARG-179; ARG-190; ARG-226;
RP   SER-227; ARG-259; ARG-280; ALA-281; PRO-363; ARG-384; HIS-393; TRP-409;
RP   CYS-426; MET-875; ILE-876; PHE-896; ILE-934; PHE-940; CYS-946; HIS-946;
RP   LEU-987; GLY-1316; VAL-1339; MET-1344; PRO-1355; VAL-1385; GLY-1418;
RP   PRO-1427; CYS-1453; HIS-1462; SER-1472; TYR-1485; GLU-1503 DEL; LYS-1503;
RP   VAL-1545; ARG-1555; GLY-1608; LEU-1630; ASN-1638; SER-1642; VAL-1662;
RP   PRO-1667; PHE-1677; THR-1683; SER-1692; CYS-1694; GLY-1727; ARG-1741;
RP   PHE-1766 DEL; PHE-1771; THR-1783; VAL-1783 AND THR-1792, VARIANTS
RP   ICEGTC SER-90; GLN-101; SER-178; MET-252; ARG-290; HIS-393; ILE-896;
RP   ALA-944; GLN-1213; CYS-1254; THR-1325; PRO-1328; LEU-1357; ARG-1376;
RP   ASP-1429; HIS-1462; LYS-1511; VAL-1619; SER-1684; PRO-1724; CYS-1781 AND
RP   TRP-1861, AND VARIANTS GLN-542 AND CYS-1575.
RX   PubMed=23195492; DOI=10.1016/j.eplepsyres.2012.06.006;
RA   Wang J.W., Shi X.Y., Kurahashi H., Hwang S.K., Ishii A., Higurashi N.,
RA   Kaneko S., Hirose S.;
RT   "Prevalence of SCN1A mutations in children with suspected Dravet syndrome
RT   and intractable childhood epilepsy.";
RL   Epilepsy Res. 102:195-200(2012).
RN   [86]
RP   VARIANTS DRVT ASN-194 AND ASP-1238.
RX   PubMed=23662938; DOI=10.1111/epi.12203;
RA   Kodera H., Kato M., Nord A.S., Walsh T., Lee M., Yamanaka G., Tohyama J.,
RA   Nakamura K., Nakagawa E., Ikeda T., Ben-Zeev B., Lev D., Lerman-Sagie T.,
RA   Straussberg R., Tanabe S., Ueda K., Amamoto M., Ohta S., Nonoda Y.,
RA   Nishiyama K., Tsurusaki Y., Nakashima M., Miyake N., Hayasaka K.,
RA   King M.C., Matsumoto N., Saitsu H.;
RT   "Targeted capture and sequencing for detection of mutations causing early
RT   onset epileptic encephalopathy.";
RL   Epilepsia 54:1262-1269(2013).
RN   [87]
RP   VARIANT ALA-1275.
RX   PubMed=23647072; DOI=10.1111/epi.12201;
RA   Veeramah K.R., Johnstone L., Karafet T.M., Wolf D., Sprissler R.,
RA   Salogiannis J., Barth-Maron A., Greenberg M.E., Stuhlmann T., Weinert S.,
RA   Jentsch T.J., Pazzi M., Restifo L.L., Talwar D., Erickson R.P.,
RA   Hammer M.F.;
RT   "Exome sequencing reveals new causal mutations in children with epileptic
RT   encephalopathies.";
RL   Epilepsia 54:1270-1281(2013).
RN   [88]
RP   VARIANTS ASN-45 AND TRP-1988, AND VARIANT ICEGTC SER-359.
RX   PubMed=23708187; DOI=10.1038/ng.2646;
RA   Carvill G.L., Heavin S.B., Yendle S.C., McMahon J.M., O'Roak B.J., Cook J.,
RA   Khan A., Dorschner M.O., Weaver M., Calvert S., Malone S., Wallace G.,
RA   Stanley T., Bye A.M., Bleasel A., Howell K.B., Kivity S., Mackay M.T.,
RA   Rodriguez-Casero V., Webster R., Korczyn A., Afawi Z., Zelnick N.,
RA   Lerman-Sagie T., Lev D., Moeller R.S., Gill D., Andrade D.M., Freeman J.L.,
RA   Sadleir L.G., Shendure J., Berkovic S.F., Scheffer I.E., Mefford H.C.;
RT   "Targeted resequencing in epileptic encephalopathies identifies de novo
RT   mutations in CHD2 and SYNGAP1.";
RL   Nat. Genet. 45:825-830(2013).
RN   [89]
RP   VARIANT DEE6B LEU-422.
RX   PubMed=24776920; DOI=10.1684/epd.2014.0649;
RA   Ohashi T., Akasaka N., Kobayashi Y., Magara S., Kawashima H., Matsumoto N.,
RA   Saitsu H., Tohyama J.;
RT   "Infantile epileptic encephalopathy with a hyperkinetic movement disorder
RT   and hand stereotypies associated with a novel SCN1A mutation.";
RL   Epileptic Disord. 16:208-212(2014).
RN   [90]
RP   VARIANTS DRVT THR-113; 450-GLN--LYS-2009 DEL AND ARG-1588.
RX   PubMed=25818041; DOI=10.1111/epi.12954;
RA   Mercimek-Mahmutoglu S., Patel J., Cordeiro D., Hewson S., Callen D.,
RA   Donner E.J., Hahn C.D., Kannu P., Kobayashi J., Minassian B.A., Moharir M.,
RA   Siriwardena K., Weiss S.K., Weksberg R., Snead O.C. III;
RT   "Diagnostic yield of genetic testing in epileptic encephalopathy in
RT   childhood.";
RL   Epilepsia 56:707-716(2015).
RN   [91]
RP   VARIANTS LEU-982; CYS-1575 AND SER-1674.
RX   PubMed=26311622; DOI=10.1016/j.eplepsyres.2015.08.001;
RA   Saitoh M., Ishii A., Ihara Y., Hoshino A., Terashima H., Kubota M.,
RA   Kikuchi K., Yamanaka G., Amemiya K., Hirose S., Mizuguchi M.;
RT   "Missense mutations in sodium channel SCN1A and SCN2A predispose children
RT   to encephalopathy with severe febrile seizures.";
RL   Epilepsy Res. 117:1-6(2015).
RN   [92]
RP   VARIANT VAL-1440.
RX   PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009;
RA   D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T.,
RA   Sestan N., Walsh C.A.;
RT   "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates
RT   Multiple Genetic Mechanisms.";
RL   Neuron 88:910-917(2015).
RN   [93]
RP   VARIANTS DRVT GLN-101; 1284-TRP--LYS-2009 DEL AND LEU-1345.
RX   PubMed=26993267; DOI=10.1136/jmedgenet-2015-103263;
RA   Trump N., McTague A., Brittain H., Papandreou A., Meyer E., Ngoh A.,
RA   Palmer R., Morrogh D., Boustred C., Hurst J.A., Jenkins L., Kurian M.A.,
RA   Scott R.H.;
RT   "Improving diagnosis and broadening the phenotypes in early-onset seizure
RT   and severe developmental delay disorders through gene panel analysis.";
RL   J. Med. Genet. 53:310-317(2016).
RN   [94]
RP   VARIANT DRVT HIS-393.
RX   PubMed=28544625; DOI=10.1002/ajmg.a.38282;
RA   Le S.V., Le P.H.T., Le T.K.V., Kieu Huynh T.T., Hang Do T.T.;
RT   "A mutation in GABRB3 associated with Dravet syndrome.";
RL   Am. J. Med. Genet. A 173:2126-2131(2017).
RN   [95]
RP   VARIANTS DRVT ARG-190; PRO-228; ILE-1605 AND GLN-1645, AND VARIANT ASP-616.
RX   PubMed=27864847; DOI=10.1002/humu.23149;
RG   Clinical Study Group;
RA   Parrini E., Marini C., Mei D., Galuppi A., Cellini E., Pucatti D.,
RA   Chiti L., Rutigliano D., Bianchini C., Virdo S., De Vita D., Bigoni S.,
RA   Barba C., Mari F., Montomoli M., Pisano T., Rosati A., Guerrini R.;
RT   "Diagnostic targeted resequencing in 349 patients with drug-resistant
RT   pediatric epilepsies identifies causative mutations in 30 different
RT   genes.";
RL   Hum. Mutat. 38:216-225(2017).
RN   [96]
RP   INVOLVEMENT IN DEE6B, AND VARIANTS DEE6B MET-226 AND SER-1345.
RX   PubMed=28794249; DOI=10.1212/wnl.0000000000004331;
RG   DDD Study;
RA   Sadleir L.G., Mountier E.I., Gill D., Davis S., Joshi C., DeVile C.,
RA   Kurian M.A., Mandelstam S., Wirrell E., Nickels K.C., Murali H.R.,
RA   Carvill G., Myers C.T., Mefford H.C., Scheffer I.E.;
RT   "Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early
RT   profound Thr226Met phenotype.";
RL   Neurology 89:1035-1042(2017).
RN   [97]
RP   VARIANT GLN-187.
RX   PubMed=30500825; DOI=10.1371/journal.pgen.1007671;
RA   Hiatt S.M., Neu M.B., Ramaker R.C., Hardigan A.A., Prokop J.W.,
RA   Hancarova M., Prchalova D., Havlovicova M., Prchal J., Stranecky V.,
RA   Yim D.K.C., Powis Z., Keren B., Nava C., Mignot C., Rio M.,
RA   Revah-Politi A., Hemati P., Stong N., Iglesias A.D., Suchy S.F.,
RA   Willaert R., Wentzensen I.M., Wheeler P.G., Brick L., Kozenko M.,
RA   Hurst A.C.E., Wheless J.W., Lacassie Y., Myers R.M., Barsh G.S.,
RA   Sedlacek Z., Cooper G.M.;
RT   "De novo mutations in the GTP/GDP-binding region of RALA, a RAS-like small
RT   GTPase, cause intellectual disability and developmental delay.";
RL   PLoS Genet. 14:e1007671-e1007671(2018).
RN   [98]
RP   VARIANT SER-541.
RX   PubMed=36977636; DOI=10.1093/cercor/bhad051;
RA   Knierim E., Vogt J., Kintscher M., Ponomarenko A., Baumgart J., Beed P.,
RA   Korotkova T., Trimbuch T., Panzer A., Steinlein O.K., Stephani U.,
RA   Escayg A., Koko M., Liu Y., Lerche H., Schmitz D., Nitsch R., Schuelke M.;
RT   "Mutations in plasticity-related-gene-1 (PRG-1) protein contribute to
RT   hippocampal seizure susceptibility and modify epileptic phenotype.";
RL   Cereb. Cortex 0:0-0(2023).
RN   [99]
RP   VARIANT CYS-1596, AND CHARACTERIZATION OF VARIANT CYS-1596.
RX   PubMed=38339022; DOI=10.3390/ijms25031745;
RA   Witkowski G., Szulczyk B., Nurowska E., Jurek M., Pasierski M., Lipiec A.,
RA   Charzewska A., Dawidziuk M., Milewski M., Owsiak S., Rola R.,
RA   Sienkiewicz Jarosz H., Hoffman-Zacharska D.;
RT   "Functional characteristics of the Nav1.1 p.Arg1596Cys mutation associated
RT   with varying severity of epilepsy phenotypes.";
RL   Int. J. Mol. Sci. 25:0-0(2024).
CC   -!- FUNCTION: Pore-forming subunit of Nav1.1, a voltage-gated sodium (Nav)
CC       channel that directly mediates the depolarizing phase of action
CC       potentials in excitable membranes. Navs, also called VGSCs (voltage-
CC       gated sodium channels) or VDSCs (voltage-dependent sodium channels),
CC       operate by switching between closed and open conformations depending on
CC       the voltage difference across the membrane. In the open conformation
CC       they allow Na(+) ions to selectively pass through the pore, along their
CC       electrochemical gradient. The influx of Na(+) ions provokes membrane
CC       depolarization, initiating the propagation of electrical signals
CC       throughout cells and tissues (PubMed:14672992). By regulating the
CC       excitability of neurons, ensures that they respond appropriately to
CC       synaptic inputs, maintaining the balance between excitation and
CC       inhibition in brain neural circuits (By similarity). Nav1.1 plays a
CC       role in controlling the excitability and action potential propagation
CC       from somatosensory neurons, thereby contributing to the sensory
CC       perception of mechanically-induced pain (By similarity).
CC       {ECO:0000250|UniProtKB:A2APX8, ECO:0000269|PubMed:14672992}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Na(+)(in) = Na(+)(out); Xref=Rhea:RHEA:34963,
CC         ChEBI:CHEBI:29101; Evidence={ECO:0000269|PubMed:14672992};
CC   -!- ACTIVITY REGULATION: Activated by the spider toxins Hm1a and Hm1b
CC       (H.maculata, AC P60992 and AC P0DOC5) eliciting acute pain and
CC       mechanical allodynia (By similarity). Inhibited by the conotoxin GVIIJ
CC       (PubMed:24497506). Inhibited by the spider beta/delta-theraphotoxin-
CC       Pre1a (PubMed:28428547). {ECO:0000250|UniProtKB:A2APX8,
CC       ECO:0000269|PubMed:24497506, ECO:0000269|PubMed:28428547}.
CC   -!- SUBUNIT: The Nav1.1 voltage-gated sodium channel consists of an ion-
CC       conducting alpha subunit SCN1A which is functional on its own regulated
CC       by one or more beta-1 (SCN1B), beta-2 (SCN2B), beta-3 (SCN3B) and beta-
CC       4 (SCN4B) subunits (PubMed:15525788, PubMed:33712547). SCN1B and SCN3B
CC       are non-covalently associated with SCN1A. SCN2B and SCN4B are
CC       disulfide-linked to SCN1A (PubMed:33712547). SCN1B regulates both the
CC       expression at the plasma membrane and the voltage dependence of Nav1.1
CC       inactivation (PubMed:15525788, PubMed:17928445). SCN3B and SCN4B reduce
CC       Nav1.1 conductance (PubMed:33712547). Probably interacts with TMEM233;
CC       modulates the gating properties of NaV1.1 (Probable). Interacts with
CC       FGF13; regulates the steady-state inactivation of Nav.1.1
CC       (PubMed:21566136). {ECO:0000269|PubMed:15525788,
CC       ECO:0000269|PubMed:17928445, ECO:0000269|PubMed:21566136,
CC       ECO:0000269|PubMed:33712547, ECO:0000305|PubMed:37117223}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:14672992,
CC       ECO:0000269|PubMed:17928445}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:33712547}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P35498-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35498-2; Sequence=VSP_001031;
CC       Name=3;
CC         IsoId=P35498-3; Sequence=VSP_045399;
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1, S2, S3, S5, S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at every
CC       third position. {ECO:0000305}.
CC   -!- DOMAIN: The S3b-S4 and S1-S2 loops of repeat IV are targeted by
CC       H.maculata toxins Hm1a and Hm1b, leading to inhibit fast inactivation
CC       of Nav1.1/SCN1A. Selectivity for H.maculata toxins Hm1a and Hm1b
CC       depends on S1-S2 loops of repeat IV. {ECO:0000250|UniProtKB:A2APX8}.
CC   -!- PTM: Phosphorylation at Ser-1516 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and reduces
CC       peak sodium currents. {ECO:0000250|UniProtKB:P04775}.
CC   -!- DISEASE: Generalized epilepsy with febrile seizures plus 2 (GEFSP2)
CC       [MIM:604403]: A rare autosomal dominant, familial condition with
CC       incomplete penetrance and large intrafamilial variability. Patients
CC       display febrile seizures persisting sometimes beyond the age of 6 years
CC       and/or a variety of afebrile seizure types. This disease combines
CC       febrile seizures, generalized seizures often precipitated by fever at
CC       age 6 years or more, and partial seizures, with a variable degree of
CC       severity. {ECO:0000269|PubMed:10742094, ECO:0000269|PubMed:11254444,
CC       ECO:0000269|PubMed:11254445, ECO:0000269|PubMed:11524484,
CC       ECO:0000269|PubMed:11756608, ECO:0000269|PubMed:12535936,
CC       ECO:0000269|PubMed:12576172, ECO:0000269|PubMed:12919402,
CC       ECO:0000269|PubMed:14672992, ECO:0000269|PubMed:15525788,
CC       ECO:0000269|PubMed:15694566, ECO:0000269|PubMed:15715999,
CC       ECO:0000269|PubMed:16525050, ECO:0000269|PubMed:17347258,
CC       ECO:0000269|PubMed:17507202, ECO:0000269|PubMed:17561957,
CC       ECO:0000269|PubMed:17927801, ECO:0000269|PubMed:17928445,
CC       ECO:0000269|PubMed:18251839, ECO:0000269|PubMed:18413471,
CC       ECO:0000269|PubMed:18566737, ECO:0000269|PubMed:19339291,
CC       ECO:0000269|PubMed:19464195, ECO:0000269|PubMed:19522081,
CC       ECO:0000269|PubMed:20117752, ECO:0000269|PubMed:20550552,
CC       ECO:0000269|PubMed:20600615, ECO:0000269|PubMed:20729507,
CC       ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:21864321}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Dravet syndrome (DRVT) [MIM:607208]: A severe form of
CC       epileptic encephalopathy characterized by generalized tonic, clonic,
CC       and tonic-clonic seizures that are initially induced by fever and begin
CC       during the first year of life. Later, patients also manifest other
CC       seizure types, including absence, myoclonic, and simple and complex
CC       partial seizures. Psychomotor development delay is observed around the
CC       second year of life. Some patients manifest a borderline disease
CC       phenotype and do not necessarily fulfill all diagnostic criteria for
CC       core DRVT. DRVT is considered to be the most severe phenotype within
CC       the spectrum of generalized epilepsies with febrile seizures-plus.
CC       {ECO:0000269|PubMed:11359211, ECO:0000269|PubMed:12083760,
CC       ECO:0000269|PubMed:12566275, ECO:0000269|PubMed:12754708,
CC       ECO:0000269|PubMed:12821740, ECO:0000269|PubMed:14504318,
CC       ECO:0000269|PubMed:14672992, ECO:0000269|PubMed:14738421,
CC       ECO:0000269|PubMed:15087100, ECO:0000269|PubMed:15944908,
CC       ECO:0000269|PubMed:16122630, ECO:0000269|PubMed:16458823,
CC       ECO:0000269|PubMed:16713920, ECO:0000269|PubMed:17054684,
CC       ECO:0000269|PubMed:17054685, ECO:0000269|PubMed:17129991,
CC       ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:17561957,
CC       ECO:0000269|PubMed:18413471, ECO:0000269|PubMed:18639757,
CC       ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:19522081,
CC       ECO:0000269|PubMed:19563458, ECO:0000269|PubMed:19589774,
CC       ECO:0000269|PubMed:19783390, ECO:0000269|PubMed:20110217,
CC       ECO:0000269|PubMed:20431604, ECO:0000269|PubMed:20452746,
CC       ECO:0000269|PubMed:20522430, ECO:0000269|PubMed:20729507,
CC       ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:21555645,
CC       ECO:0000269|PubMed:21719429, ECO:0000269|PubMed:21753172,
CC       ECO:0000269|PubMed:21864321, ECO:0000269|PubMed:22092154,
CC       ECO:0000269|PubMed:22612257, ECO:0000269|PubMed:23195492,
CC       ECO:0000269|PubMed:23662938, ECO:0000269|PubMed:23708187,
CC       ECO:0000269|PubMed:25818041, ECO:0000269|PubMed:26993267,
CC       ECO:0000269|PubMed:27864847, ECO:0000269|PubMed:28544625,
CC       ECO:0000269|PubMed:33712547}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Intractable childhood epilepsy with generalized tonic-clonic
CC       seizures (ICEGTC) [MIM:607208]: A disorder characterized by generalized
CC       tonic-clonic seizures beginning usually in infancy and induced by
CC       fever. Seizures are associated with subsequent mental decline, as well
CC       as ataxia or hypotonia. ICEGTC is similar to SMEI, except for the
CC       absence of myoclonic seizures. {ECO:0000269|PubMed:12566275,
CC       ECO:0000269|PubMed:16210358, ECO:0000269|PubMed:17507202,
CC       ECO:0000269|PubMed:23195492, ECO:0000269|PubMed:23708187}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Migraine, familial hemiplegic, 3 (FHM3) [MIM:609634]: A
CC       subtype of migraine associated with transient blindness in some
CC       families. Migraine is a disabling symptom complex of periodic
CC       headaches, usually temporal and unilateral. Headaches are often
CC       accompanied by irritability, nausea, vomiting and photophobia, preceded
CC       by constriction of the cranial arteries. The two major subtypes are
CC       common migraine (migraine without aura) and classic migraine (migraine
CC       with aura). Classic migraine is characterized by recurrent attacks of
CC       reversible neurological symptoms (aura) that precede or accompany the
CC       headache. Aura may include a combination of sensory disturbances, such
CC       as blurred vision, hallucinations, vertigo, numbness and difficulty in
CC       concentrating and speaking. {ECO:0000269|PubMed:16054936,
CC       ECO:0000269|PubMed:17397047, ECO:0000269|PubMed:18021921,
CC       ECO:0000269|PubMed:19332696, ECO:0000269|PubMed:33712547}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Febrile seizures, familial, 3A (FEB3A) [MIM:604403]: Seizures
CC       associated with febrile episodes in childhood without any evidence of
CC       intracranial infection or defined pathologic or traumatic cause. It is
CC       a common condition, affecting 2-5% of children aged 3 months to 5
CC       years. The majority are simple febrile seizures (generally defined as
CC       generalized onset, single seizures with a duration of less than 30
CC       minutes). Complex febrile seizures are characterized by focal onset,
CC       duration greater than 30 minutes, and/or more than one seizure in a 24
CC       hour period. The likelihood of developing epilepsy following simple
CC       febrile seizures is low. Complex febrile seizures are associated with a
CC       moderately increased incidence of epilepsy.
CC       {ECO:0000269|PubMed:16326807, ECO:0000269|PubMed:19522081}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Developmental and epileptic encephalopathy 6B (DEE6B)
CC       [MIM:619317]: A form of epileptic encephalopathy, a heterogeneous group
CC       of severe early-onset epilepsies characterized by refractory seizures,
CC       neurodevelopmental impairment, and poor prognosis. Development is
CC       normal prior to seizure onset, after which cognitive and motor delays
CC       become apparent. DEE6B is an autosomal dominant condition characterized
CC       by onset of seizures in early infancy, profoundly impaired intellectual
CC       development, and a hyperkinetic movement disorder.
CC       {ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:24776920,
CC       ECO:0000269|PubMed:28794249}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=SCN1A mutations may be involved in Panayiotopoulos
CC       syndrome, a benign age-related focal seizure disorder occurring in
CC       early and mid-childhood. It is characterized by seizures, often
CC       prolonged, with predominantly autonomic symptoms, and by an
CC       electroencephalogram that shows shifting and/or multiple foci, often
CC       with occipital predominance. Autonomic seizures in Panayiotopoulos
CC       syndrome consist of episodes of disturbed autonomic function with
CC       emesis as the predominant symptom. Cardiorespiratory arrest is
CC       exceptional. {ECO:0000269|PubMed:17679682, ECO:0000269|PubMed:19339291,
CC       ECO:0000269|PubMed:19522081}.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.1/SCN1A subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF225985; AAK00217.1; -; mRNA.
DR   EMBL; AY043484; AAK95360.1; -; mRNA.
DR   EMBL; AB093548; BAC21101.1; -; mRNA.
DR   EMBL; AB093549; BAC21102.1; -; mRNA.
DR   EMBL; AB098335; BAC45228.1; -; mRNA.
DR   EMBL; AC010127; AAX81984.1; -; Genomic_DNA.
DR   EMBL; S71446; AAB31605.1; -; Genomic_DNA.
DR   EMBL; X65362; CAA46439.1; -; mRNA.
DR   EMBL; M91803; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS33316.1; -. [P35498-2]
DR   CCDS; CCDS54413.1; -. [P35498-1]
DR   CCDS; CCDS54414.1; -. [P35498-3]
DR   PIR; I52964; I52964.
DR   PIR; S29184; S29184.
DR   RefSeq; NP_001159435.1; NM_001165963.4. [P35498-1]
DR   RefSeq; NP_001159436.1; NM_001165964.3. [P35498-3]
DR   RefSeq; NP_001189364.1; NM_001202435.3. [P35498-1]
DR   RefSeq; NP_001340877.1; NM_001353948.2. [P35498-1]
DR   RefSeq; NP_001340878.1; NM_001353949.2. [P35498-2]
DR   RefSeq; NP_001340879.1; NM_001353950.2. [P35498-2]
DR   RefSeq; NP_001340880.1; NM_001353951.2. [P35498-2]
DR   RefSeq; NP_001340881.1; NM_001353952.2. [P35498-2]
DR   RefSeq; NP_001340886.1; NM_001353957.2. [P35498-3]
DR   RefSeq; NP_001340887.1; NM_001353958.2. [P35498-3]
DR   RefSeq; NP_008851.3; NM_006920.4. [P35498-2]
DR   RefSeq; XP_011509904.1; XM_011511602.2.
DR   RefSeq; XP_011509906.1; XM_011511604.2.
DR   RefSeq; XP_011509908.1; XM_011511606.2.
DR   RefSeq; XP_016860133.1; XM_017004644.1.
DR   RefSeq; XP_016860134.1; XM_017004645.1.
DR   RefSeq; XP_016860135.1; XM_017004646.1.
DR   RefSeq; XP_016860136.1; XM_017004647.1.
DR   RefSeq; XP_016860137.1; XM_017004648.1.
DR   RefSeq; XP_016860138.1; XM_017004649.1.
DR   RefSeq; XP_016860140.1; XM_017004651.1.
DR   RefSeq; XP_016860141.1; XM_017004652.1.
DR   PDB; 7DTD; EM; 3.30 A; A=1-2009.
DR   PDBsum; 7DTD; -.
DR   AlphaFoldDB; P35498; -.
DR   EMDB; EMD-30851; -.
DR   SMR; P35498; -.
DR   BioGRID; 112228; 11.
DR   ComplexPortal; CPX-8639; Nav1.1 voltage-gated sodium channel complex, SCN1B-SCN2B variant.
DR   ComplexPortal; CPX-8640; Nav1.1 voltage-gated sodium channel complex, SCN2B-SCN3B variant.
DR   ComplexPortal; CPX-8641; Nav1.1 voltage-gated sodium channel complex, SCN1B-SCN4B variant.
DR   ComplexPortal; CPX-8642; Nav1.1 voltage-gated sodium channel complex, SCN3B-SCN4B variant.
DR   DIP; DIP-59851N; -.
DR   FunCoup; P35498; 1049.
DR   IntAct; P35498; 6.
DR   MINT; P35498; -.
DR   STRING; 9606.ENSP00000303540; -.
DR   BindingDB; P35498; -.
DR   ChEMBL; CHEMBL1845; -.
DR   DrugBank; DB09088; Amylocaine.
DR   DrugBank; DB09009; Articaine.
DR   DrugBank; DB13746; Bioallethrin.
DR   DrugBank; DB05541; Brivaracetam.
DR   DrugBank; DB00564; Carbamazepine.
DR   DrugBank; DB06119; Cenobamate.
DR   DrugBank; DB01161; Chloroprocaine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB13269; Dichlorobenzyl alcohol.
DR   DrugBank; DB13961; Fish oil.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB01595; Nitrazepam.
DR   DrugBank; DB00776; Oxcarbazepine.
DR   DrugBank; DB11186; Pentoxyverine.
DR   DrugBank; DB04930; Permethrin.
DR   DrugBank; DB01121; Phenacemide.
DR   DrugBank; DB01438; Phenazopyridine.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB09345; Pramocaine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB09342; Propoxycaine.
DR   DrugBank; DB00243; Ranolazine.
DR   DrugBank; DB09085; Tetracaine.
DR   DrugBank; DB05232; Tetrodotoxin.
DR   DrugBank; DB00273; Topiramate.
DR   DrugBank; DB00313; Valproic acid.
DR   DrugBank; DB00909; Zonisamide.
DR   DrugCentral; P35498; -.
DR   GuidetoPHARMACOLOGY; 578; -.
DR   TCDB; 1.A.1.10.7; the voltage-gated ion channel (vic) superfamily.
DR   GlyCosmos; P35498; 9 sites, No reported glycans.
DR   GlyGen; P35498; 10 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P35498; -.
DR   PhosphoSitePlus; P35498; -.
DR   SwissPalm; P35498; -.
DR   BioMuta; SCN1A; -.
DR   DMDM; 12644229; -.
DR   jPOST; P35498; -.
DR   MassIVE; P35498; -.
DR   PaxDb; 9606-ENSP00000303540; -.
DR   PeptideAtlas; P35498; -.
DR   ProteomicsDB; 20245; -.
DR   ProteomicsDB; 55069; -. [P35498-1]
DR   ProteomicsDB; 55070; -. [P35498-2]
DR   ABCD; P35498; 3 sequenced antibodies.
DR   Antibodypedia; 47608; 222 antibodies from 32 providers.
DR   DNASU; 6323; -.
DR   Ensembl; ENST00000303395.9; ENSP00000303540.4; ENSG00000144285.24. [P35498-1]
DR   Ensembl; ENST00000375405.7; ENSP00000364554.3; ENSG00000144285.24. [P35498-2]
DR   Ensembl; ENST00000409050.2; ENSP00000386312.1; ENSG00000144285.24. [P35498-3]
DR   Ensembl; ENST00000635750.1; ENSP00000490799.1; ENSG00000144285.24. [P35498-2]
DR   Ensembl; ENST00000637988.1; ENSP00000490780.1; ENSG00000144285.24. [P35498-2]
DR   Ensembl; ENST00000674923.1; ENSP00000501589.1; ENSG00000144285.24. [P35498-1]
DR   GeneID; 6323; -.
DR   KEGG; hsa:6323; -.
DR   MANE-Select; ENST00000674923.1; ENSP00000501589.1; NM_001165963.4; NP_001159435.1.
DR   UCSC; uc061pes.1; human. [P35498-1]
DR   AGR; HGNC:10585; -.
DR   CTD; 6323; -.
DR   DisGeNET; 6323; -.
DR   GeneCards; SCN1A; -.
DR   GeneReviews; SCN1A; -.
DR   HGNC; HGNC:10585; SCN1A.
DR   HPA; ENSG00000144285; Tissue enhanced (brain, retina).
DR   MalaCards; SCN1A; -.
DR   MIM; 182389; gene.
DR   MIM; 604403; phenotype.
DR   MIM; 607208; phenotype.
DR   MIM; 609634; phenotype.
DR   MIM; 619317; phenotype.
DR   neXtProt; NX_P35498; -.
DR   OpenTargets; ENSG00000144285; -.
DR   Orphanet; 33069; Dravet syndrome.
DR   Orphanet; 293181; Epilepsy of infancy with migrating focal seizures.
DR   Orphanet; 1942; Epilepsy with myoclonic-atonic seizures.
DR   Orphanet; 569; Familial or sporadic hemiplegic migraine.
DR   Orphanet; 36387; Genetic epilepsy with febrile seizure plus.
DR   Orphanet; 2382; Lennox-Gastaut syndrome.
DR   Orphanet; 442835; Non-specific early-onset epileptic encephalopathy.
DR   PharmGKB; PA301; -.
DR   VEuPathDB; HostDB:ENSG00000144285; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   GeneTree; ENSGT00940000154224; -.
DR   HOGENOM; CLU_000540_5_0_1; -.
DR   InParanoid; P35498; -.
DR   OMA; KTELTMS; -.
DR   OrthoDB; 2984333at2759; -.
DR   PAN-GO; P35498; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P35498; -.
DR   TreeFam; TF323985; -.
DR   PathwayCommons; P35498; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   SignaLink; P35498; -.
DR   SIGNOR; P35498; -.
DR   BioGRID-ORCS; 6323; 9 hits in 1153 CRISPR screens.
DR   ChiTaRS; SCN1A; human.
DR   GeneWiki; Nav1.1; -.
DR   GenomeRNAi; 6323; -.
DR   Pharos; P35498; Tclin.
DR   PRO; PR:P35498; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P35498; protein.
DR   Bgee; ENSG00000144285; Expressed in Brodmann (1909) area 23 and 114 other cell types or tissues.
DR   ExpressionAtlas; P35498; baseline and differential.
DR   GO; GO:0043194; C:axon initial segment; IEA:Ensembl.
DR   GO; GO:0014704; C:intercalated disc; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0033268; C:node of Ranvier; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0030315; C:T-tubule; IEA:Ensembl.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IBA:GO_Central.
DR   GO; GO:0030018; C:Z disc; ISS:BHF-UCL.
DR   GO; GO:0099508; F:voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; IMP:UniProtKB.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; IMP:BHF-UCL.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IMP:UniProtKB.
DR   GO; GO:0021675; P:nerve development; IEA:Ensembl.
DR   GO; GO:0050884; P:neuromuscular process controlling posture; IEA:Ensembl.
DR   GO; GO:0019228; P:neuronal action potential; IEA:Ensembl.
DR   GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IBA:GO_Central.
DR   GO; GO:0006814; P:sodium ion transport; NAS:UniProtKB.
DR   CDD; cd13433; Na_channel_gate; 1.
DR   FunFam; 1.10.238.10:FF:000002; Sodium channel protein; 1.
DR   FunFam; 1.10.287.70:FF:000001; Sodium channel protein; 1.
DR   FunFam; 1.10.287.70:FF:000006; Sodium channel protein; 1.
DR   FunFam; 1.20.120.350:FF:000002; Sodium channel protein; 1.
DR   FunFam; 1.20.120.350:FF:000004; Sodium channel protein; 1.
DR   FunFam; 1.20.120.350:FF:000005; Sodium channel protein; 1.
DR   FunFam; 1.20.5.1190:FF:000001; Sodium channel protein; 1.
DR   FunFam; 1.20.120.350:FF:000003; Voltage-dependent sodium channel; 1.
DR   Gene3D; 1.10.287.70; -; 4.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 1.20.5.1190; iswi atpase; 1.
DR   Gene3D; 1.20.120.350; Voltage-gated potassium channels. Chain C; 4.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR008051; Na_channel_a1su.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR044564; Na_chnl_inactivation_gate.
DR   InterPro; IPR010526; Na_trans_assoc_dom.
DR   InterPro; IPR024583; Na_trans_cytopl.
DR   InterPro; IPR043203; VGCC_Ca_Na.
DR   InterPro; IPR027359; Volt_channel_dom_sf.
DR   PANTHER; PTHR10037:SF280; SODIUM CHANNEL PROTEIN TYPE 1 SUBUNIT ALPHA; 1.
DR   PANTHER; PTHR10037; VOLTAGE-GATED CATION CHANNEL CALCIUM AND SODIUM; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF24609; IQ_SCN5A_C; 1.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   Pfam; PF11933; Na_trans_cytopl; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   PRINTS; PR01664; NACHANNEL1.
DR   SUPFAM; SSF81324; Voltage-gated potassium channels; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autism; Autism spectrum disorder;
KW   Cell membrane; Disease variant; Disulfide bond; Epilepsy; Glycoprotein;
KW   Ion channel; Ion transport; Membrane; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repeat; Sodium;
KW   Sodium channel; Sodium transport; Transmembrane; Transmembrane helix;
KW   Transport; Voltage-gated channel.
FT   CHAIN           1..2009
FT                   /note="Sodium channel protein type 1 subunit alpha"
FT                   /id="PRO_0000048489"
FT   TOPO_DOM        1..128
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        129..146
FT                   /note="Helical; Name=S1 of repeat I"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        147..152
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        153..177
FT                   /note="Helical; Name=S2 of repeat I"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        178..188
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        189..205
FT                   /note="Helical; Name=S3 of repeat I"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        206..213
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        214..235
FT                   /note="Helical; Name=S4 of repeat I"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        236..245
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        246..269
FT                   /note="Helical; Name=S5 of repeat I"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        270..369
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        370..384
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        385..397
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        398..423
FT                   /note="Helical; Name=S6 of repeat I"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        424..768
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        769..787
FT                   /note="Helical; Name=S1 of repeat II"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        788..797
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        798..820
FT                   /note="Helical; Name=S2 of repeat II"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        821..830
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        831..849
FT                   /note="Helical; Name=S3 of repeat II"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        850..854
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        855..874
FT                   /note="Helical; Name=S4 of repeat II"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        875..891
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        892..912
FT                   /note="Helical; Name=S5 of repeat II"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        913..938
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        939..952
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        953..965
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        966..992
FT                   /note="Helical; Name=S6 of repeat II"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        993..1218
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1219..1237
FT                   /note="Helical; Name=S1 of repeat III"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1238..1250
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1251..1276
FT                   /note="Helical; Name=S2 of repeat III"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1277..1278
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1279..1304
FT                   /note="Helical; Name=S3 of repeat III"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1305..1313
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1314..1332
FT                   /note="Helical; Name=S4 of repeat III"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1333..1345
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1346..1369
FT                   /note="Helical; Name=S5 of repeat III"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1370..1415
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        1416..1433
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1434..1457
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1458..1483
FT                   /note="Helical; Name=S6 of repeat III"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1484..1541
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1542..1560
FT                   /note="Helical; Name=S1 of repeat IV"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1561..1571
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1572..1593
FT                   /note="Helical; Name=S2 of repeat IV"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1594..1601
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1602..1623
FT                   /note="Helical; Name=S3 of repeat IV"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1624..1636
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1637..1655
FT                   /note="Helical; Name=S4 of repeat IV"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1656..1665
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1666..1688
FT                   /note="Helical; Name=S5 of repeat IV"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1689..1711
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        1712..1726
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1727..1759
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1760..1788
FT                   /note="Helical; Name=S6 of repeat IV"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   TOPO_DOM        1789..2009
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REPEAT          110..454
FT                   /note="I"
FT                   /evidence="ECO:0000305"
FT   REPEAT          750..1022
FT                   /note="II"
FT                   /evidence="ECO:0000305"
FT   REPEAT          1200..1514
FT                   /note="III"
FT                   /evidence="ECO:0000305"
FT   REPEAT          1523..1821
FT                   /note="IV"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          1915..1944
FT                   /note="IQ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00116"
FT   REGION          28..60
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          455..529
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          584..627
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1129..1163
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1561..1571
FT                   /note="S1-S2 loop of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:A2APX8"
FT   REGION          1619..1636
FT                   /note="S3b-S4 loop of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:A2APX8"
FT   REGION          1986..2009
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        28..48
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        456..466
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        479..492
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        495..506
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        520..529
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        593..607
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1988..2009
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            1574
FT                   /note="Key residue that permits the spider beta/delta-
FT                   theraphotoxin-Pre1a to inhibit fast inactivation of the
FT                   channel"
FT                   /evidence="ECO:0000269|PubMed:28428547"
FT   MOD_RES         470
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04774"
FT   MOD_RES         523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04774"
FT   MOD_RES         525
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04774"
FT   MOD_RES         550
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04774"
FT   MOD_RES         551
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2APX8"
FT   MOD_RES         607
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04774"
FT   MOD_RES         730
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P04774"
FT   MOD_RES         1516
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000250|UniProtKB:P04775"
FT   CARBOHYD        211
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        284
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        295
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        301
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        306
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        338
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   CARBOHYD        1378
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   CARBOHYD        1392
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   CARBOHYD        1403
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   DISULFID        277..345
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   DISULFID        336..351
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   DISULFID        919
FT                   /note="Interchain; with SCN2B or SCN4B"
FT                   /evidence="ECO:0000305|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   DISULFID        919
FT                   /note="Interchain; with the conotoxin GVIIJ (when the
FT                   channel is not linked to SCN2B or SCN4B; the bond to SCN2B
FT                   or SCN4B protects the channel from the inhibition by
FT                   toxin)"
FT                   /evidence="ECO:0000250|UniProtKB:P04775"
FT   DISULFID        921..927
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   DISULFID        959..968
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   DISULFID        1376..1396
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   DISULFID        1741..1756
FT                   /evidence="ECO:0000269|PubMed:33712547,
FT                   ECO:0007744|PDB:7DTD"
FT   VAR_SEQ         654..681
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_045399"
FT   VAR_SEQ         671..681
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.2, ECO:0000303|Ref.3,
FT                   ECO:0000303|Ref.4"
FT                   /id="VSP_001031"
FT   VARIANT         17
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073441"
FT   VARIANT         27
FT                   /note="R -> T (in GEFSP2; likely benign;
FT                   dbSNP:rs121917906)"
FT                   /evidence="ECO:0000269|PubMed:20729507"
FT                   /id="VAR_064229"
FT   VARIANT         45
FT                   /note="D -> N (found in patients with different types of
FT                   epilepsy; uncertain significance; dbSNP:rs531894715)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:23708187"
FT                   /id="VAR_073442"
FT   VARIANT         58
FT                   /note="G -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073443"
FT   VARIANT         61
FT                   /note="L -> F (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073444"
FT   VARIANT         63
FT                   /note="F -> L (in DRVT; uncertain significance;
FT                   dbSNP:rs121917907)"
FT                   /evidence="ECO:0000269|PubMed:20729507"
FT                   /id="VAR_064230"
FT   VARIANT         68
FT                   /note="I -> T (in DRVT; uncertain significance; borderline
FT                   phenotype; dbSNP:rs758871507)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073445"
FT   VARIANT         74
FT                   /note="S -> P (in GEFSP2; uncertain significance;
FT                   dbSNP:rs121917931)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064295"
FT   VARIANT         78
FT                   /note="E -> D (in DRVT; dbSNP:rs121917933)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054684"
FT                   /id="VAR_029660"
FT   VARIANT         79
FT                   /note="D -> H (in DRVT; borderline phenotype;
FT                   dbSNP:rs121917982)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:18930999"
FT                   /id="VAR_064346"
FT   VARIANT         79
FT                   /note="D -> N (in DRVT; dbSNP:rs121917982)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073446"
FT   VARIANT         84
FT                   /note="Y -> C (in DRVT; dbSNP:rs121917964)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:19589774, ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:23195492, ECO:0000269|PubMed:27864847"
FT                   /id="VAR_043349"
FT   VARIANT         90
FT                   /note="F -> S (in DRVT and ICEGTC; dbSNP:rs121918733)"
FT                   /evidence="ECO:0000269|PubMed:20431604,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_064231"
FT   VARIANT         91
FT                   /note="I -> T (in DRVT; dbSNP:rs121918734)"
FT                   /evidence="ECO:0000269|PubMed:20431604"
FT                   /id="VAR_064232"
FT   VARIANT         98
FT                   /note="A -> P (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073447"
FT   VARIANT         101
FT                   /note="R -> Q (in DRVT and ICEGTC; dbSNP:rs121917918)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:17561957, ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:19589774, ECO:0000269|PubMed:20431604,
FT                   ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:23195492,
FT                   ECO:0000269|PubMed:26993267"
FT                   /id="VAR_029661"
FT   VARIANT         101
FT                   /note="R -> W (in DRVT; dbSNP:rs121917965)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:20431604,
FT                   ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:23195492"
FT                   /id="VAR_064233"
FT   VARIANT         103
FT                   /note="S -> G (in DRVT; dbSNP:rs121918743)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029662"
FT   VARIANT         105
FT                   /note="T -> I (in DRVT; dbSNP:rs796053089)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073448"
FT   VARIANT         108
FT                   /note="L -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073449"
FT   VARIANT         112
FT                   /note="T -> I (in DRVT; dbSNP:rs121918745)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029663"
FT   VARIANT         113
FT                   /note="P -> T (in DRVT; dbSNP:rs794726711)"
FT                   /evidence="ECO:0000269|PubMed:25818041"
FT                   /id="VAR_078725"
FT   VARIANT         118
FT                   /note="R -> S (in DRVT; dbSNP:rs121917959)"
FT                   /evidence="ECO:0000269|PubMed:18413471"
FT                   /id="VAR_043350"
FT   VARIANT         124
FT                   /note="I -> N (in DRVT; dbSNP:rs121918761)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:20522430"
FT                   /id="VAR_064234"
FT   VARIANT         127
FT                   /note="H -> D (in DRVT; borderline phenotype;
FT                   dbSNP:rs148442069)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073450"
FT   VARIANT         145
FT                   /note="M -> T (in FEB3A; loss of function;
FT                   dbSNP:rs121918631)"
FT                   /evidence="ECO:0000269|PubMed:16326807"
FT                   /id="VAR_025366"
FT   VARIANT         162
FT                   /note="T -> P (in DRVT; dbSNP:rs121917934)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064296"
FT   VARIANT         171
FT                   /note="I -> K (in DRVT; dbSNP:rs121918766)"
FT                   /evidence="ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064235"
FT   VARIANT         171
FT                   /note="I -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073451"
FT   VARIANT         175
FT                   /note="A -> T (in DRVT; dbSNP:rs121918767)"
FT                   /evidence="ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064236"
FT   VARIANT         175
FT                   /note="A -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073452"
FT   VARIANT         177
FT                   /note="G -> E (in DRVT; results in a non-functional
FT                   channel; dbSNP:rs121918770)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054685"
FT                   /id="VAR_029664"
FT   VARIANT         178
FT                   /note="F -> S (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073453"
FT   VARIANT         179
FT                   /note="C -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073454"
FT   VARIANT         187
FT                   /note="R -> Q (found in a child with developmental
FT                   disabilities; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:30500825"
FT                   /id="VAR_085768"
FT   VARIANT         188
FT                   /note="D -> V (in GEFSP2; dbSNP:rs121917953)"
FT                   /evidence="ECO:0000269|PubMed:11254444,
FT                   ECO:0000269|PubMed:12576172"
FT                   /id="VAR_014267"
FT   VARIANT         190
FT                   /note="W -> R (in DRVT; dbSNP:rs121918773)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029665"
FT   VARIANT         191
FT                   /note="N -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073455"
FT   VARIANT         191
FT                   /note="N -> Y (in DRVT; dbSNP:rs121918762)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:20522430"
FT                   /id="VAR_064237"
FT   VARIANT         194
FT                   /note="D -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073456"
FT   VARIANT         194
FT                   /note="D -> N (in DRVT; dbSNP:rs121917935)"
FT                   /evidence="ECO:0000269|PubMed:17054684,
FT                   ECO:0000269|PubMed:19589774, ECO:0000269|PubMed:23662938,
FT                   ECO:0000269|PubMed:27864847"
FT                   /id="VAR_064238"
FT   VARIANT         199
FT                   /note="T -> R (in DRVT; borderline phenotype with spike
FT                   wave activity; dbSNP:rs121917983)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064347"
FT   VARIANT         217
FT                   /note="T -> K (in DRVT; dbSNP:rs121917936)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064297"
FT   VARIANT         218
FT                   /note="F -> L (in GEFSP2; also found in patients with
FT                   Panayiotopoulos syndrome; dbSNP:rs970867558)"
FT                   /evidence="ECO:0000269|PubMed:19339291,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073457"
FT   VARIANT         222..2009
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:11359211"
FT                   /id="VAR_085926"
FT   VARIANT         223
FT                   /note="A -> E (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073458"
FT   VARIANT         226
FT                   /note="T -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21719429"
FT                   /id="VAR_090162"
FT   VARIANT         226
FT                   /note="T -> M (in DEE6B; dbSNP:rs121917984)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:28794249"
FT                   /id="VAR_043351"
FT   VARIANT         226
FT                   /note="T -> R (in DRVT; dbSNP:rs121917984)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073459"
FT   VARIANT         227
FT                   /note="I -> S (in DRVT; borderline phenotype with spike
FT                   wave activity in some patients; results in a non-functional
FT                   channel; dbSNP:rs121917937)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054684, ECO:0000269|PubMed:17054685,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:19589774,
FT                   ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029666"
FT   VARIANT         227
FT                   /note="I -> T (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073460"
FT   VARIANT         228
FT                   /note="S -> P (in DRVT; dbSNP:rs1057519530)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078192"
FT   VARIANT         232
FT                   /note="G -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073461"
FT   VARIANT         233
FT                   /note="L -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073462"
FT   VARIANT         239
FT                   /note="A -> T (in DRVT; borderline phenotype with spike
FT                   wave activity in some patients; dbSNP:rs121917985)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:20431604"
FT                   /id="VAR_043352"
FT   VARIANT         239
FT                   /note="A -> V (in DRVT; dbSNP:rs121917909)"
FT                   /evidence="ECO:0000269|PubMed:20729507"
FT                   /id="VAR_064239"
FT   VARIANT         243
FT                   /note="S -> Y (in DRVT; dbSNP:rs794726755)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073463"
FT   VARIANT         252
FT                   /note="I -> M (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073464"
FT   VARIANT         252
FT                   /note="I -> N (in DRVT; dbSNP:rs121918780)"
FT                   /evidence="ECO:0000269|PubMed:15087100"
FT                   /id="VAR_029667"
FT   VARIANT         254
FT                   /note="T -> I (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073465"
FT   VARIANT         259
FT                   /note="S -> R (in DRVT; dbSNP:rs121918735)"
FT                   /evidence="ECO:0000269|PubMed:20431604,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_064240"
FT   VARIANT         265
FT                   /note="G -> W (in DRVT; dbSNP:rs121918749)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029668"
FT   VARIANT         277
FT                   /note="C -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073466"
FT   VARIANT         280
FT                   /note="W -> C (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18639757"
FT                   /id="VAR_073467"
FT   VARIANT         280
FT                   /note="W -> R (in DRVT; dbSNP:rs121917938)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054684, ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029669"
FT   VARIANT         281
FT                   /note="P -> A (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073468"
FT   VARIANT         281
FT                   /note="P -> L (in DRVT; dbSNP:rs796052964)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073469"
FT   VARIANT         281
FT                   /note="P -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073470"
FT   VARIANT         289
FT                   /note="E -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:22612257"
FT                   /id="VAR_072743"
FT   VARIANT         290
FT                   /note="H -> R (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073471"
FT   VARIANT         291
FT                   /note="S -> G (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073472"
FT   VARIANT         297
FT                   /note="T -> I (in DRVT; dbSNP:rs121918771)"
FT                   /evidence="ECO:0000269|PubMed:12821740"
FT                   /id="VAR_029670"
FT   VARIANT         322
FT                   /note="R -> I (in DRVT; dbSNP:rs121917928)"
FT                   /evidence="ECO:0000269|PubMed:17561957,
FT                   ECO:0000269|PubMed:18930999"
FT                   /id="VAR_064298"
FT   VARIANT         333
FT                   /note="A -> V"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073473"
FT   VARIANT         340
FT                   /note="S -> F (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073474"
FT   VARIANT         342
FT                   /note="A -> V (in DRVT; dbSNP:rs794726797)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073475"
FT   VARIANT         343
FT                   /note="G -> D (in DRVT; dbSNP:rs121918753)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:21248271"
FT                   /id="VAR_029671"
FT   VARIANT         345
FT                   /note="C -> R (in DRVT; dbSNP:rs794726782)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073476"
FT   VARIANT         351
FT                   /note="C -> W (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073477"
FT   VARIANT         355
FT                   /note="G -> D (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073478"
FT   VARIANT         356
FT                   /note="R -> G (in DRVT; dbSNP:rs121917920)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064299"
FT   VARIANT         357
FT                   /note="N -> I (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073479"
FT   VARIANT         358
FT                   /note="P -> T (in DRVT; dbSNP:rs121917923)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064300"
FT   VARIANT         359
FT                   /note="N -> S (in DRVT and ICEGTC; dbSNP:rs794726713)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:23708187"
FT                   /id="VAR_073480"
FT   VARIANT         363
FT                   /note="T -> P (in DRVT; dbSNP:rs1131691465)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073481"
FT   VARIANT         363
FT                   /note="T -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073482"
FT   VARIANT         366
FT                   /note="D -> E (in DRVT; dbSNP:rs121917958)"
FT                   /evidence="ECO:0000269|PubMed:18413471"
FT                   /id="VAR_043353"
FT   VARIANT         377
FT                   /note="R -> Q (in GEFSP2; dbSNP:rs121917957)"
FT                   /evidence="ECO:0000269|PubMed:18413471"
FT                   /id="VAR_043354"
FT   VARIANT         378
FT                   /note="L -> Q (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073483"
FT   VARIANT         379
FT                   /note="M -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:22612257"
FT                   /id="VAR_072744"
FT   VARIANT         382
FT                   /note="D -> N (found in a patient with an unclassified form
FT                   of epilepsy; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073484"
FT   VARIANT         383
FT                   /note="F -> L (in DRVT; dbSNP:rs121917939)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064301"
FT   VARIANT         384
FT                   /note="W -> R (in DRVT; borderline phenotype;
FT                   dbSNP:rs1057523858)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073485"
FT   VARIANT         388
FT                   /note="Y -> H (in GEFSP2; dbSNP:rs121918781)"
FT                   /evidence="ECO:0000269|PubMed:19464195"
FT                   /id="VAR_064241"
FT   VARIANT         393
FT                   /note="R -> C (in DRVT; also in a patient with myoclonic
FT                   astatic epilepsy; dbSNP:rs121917929)"
FT                   /evidence="ECO:0000269|PubMed:17054684,
FT                   ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:17561957,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:21248271"
FT                   /id="VAR_043355"
FT   VARIANT         393
FT                   /note="R -> H (in DRVT and ICEGTC; results in a
FT                   non-functional channel; dbSNP:rs121917927)"
FT                   /evidence="ECO:0000269|PubMed:12754708,
FT                   ECO:0000269|PubMed:17054685, ECO:0000269|PubMed:17561957,
FT                   ECO:0000269|PubMed:20431604, ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:22612257, ECO:0000269|PubMed:23195492,
FT                   ECO:0000269|PubMed:28544625"
FT                   /id="VAR_029672"
FT   VARIANT         393
FT                   /note="R -> S (in DRVT; dbSNP:rs121917929)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064302"
FT   VARIANT         395
FT                   /note="A -> P (found in a patient with cryptogenic
FT                   generalized epilepsy; likely pathogenic;
FT                   dbSNP:rs121917988)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_043356"
FT   VARIANT         400
FT                   /note="M -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073486"
FT   VARIANT         400
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073487"
FT   VARIANT         403
FT                   /note="F -> L (in DRVT; dbSNP:rs121917966)"
FT                   /evidence="ECO:0000269|PubMed:16713920,
FT                   ECO:0000269|PubMed:17347258"
FT                   /id="VAR_064303"
FT   VARIANT         403
FT                   /note="F -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073488"
FT   VARIANT         406
FT                   /note="V -> F (in DRVT; dbSNP:rs121918768)"
FT                   /evidence="ECO:0000269|PubMed:19589774,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064242"
FT   VARIANT         409
FT                   /note="L -> W (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073489"
FT   VARIANT         413
FT                   /note="Y -> N (in DRVT; dbSNP:rs121917967)"
FT                   /evidence="ECO:0000269|PubMed:16713920,
FT                   ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064243"
FT   VARIANT         422
FT                   /note="V -> E (found in a patient with cryptogenic
FT                   generalized epilepsy; likely pathogenic;
FT                   dbSNP:rs121917989)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_043357"
FT   VARIANT         422
FT                   /note="V -> L (in DEE6B)"
FT                   /evidence="ECO:0000269|PubMed:24776920"
FT                   /id="VAR_085927"
FT   VARIANT         426
FT                   /note="Y -> C (in DRVT; dbSNP:rs796052973)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073490"
FT   VARIANT         426
FT                   /note="Y -> N (in DRVT; results in decreased peak current
FT                   densities; causes a negative shift in the half-maximal
FT                   steady-state inactivation and delayed recovery from fast
FT                   inactivation; dbSNP:rs121917940)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054684, ECO:0000269|PubMed:17054685"
FT                   /id="VAR_029673"
FT   VARIANT         450..2009
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:25818041"
FT                   /id="VAR_078726"
FT   VARIANT         525
FT                   /note="S -> F (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073491"
FT   VARIANT         541
FT                   /note="N -> S (found in a patient with infantile epileptic
FT                   spasms also carrying a PLPPR4 variant; uncertain
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:36977636"
FT                   /id="VAR_088154"
FT   VARIANT         542
FT                   /note="R -> Q (found in patients with different types of
FT                   epilepsy; uncertain significance; also found in patients
FT                   with autism; uncertain significance; dbSNP:rs121918817)"
FT                   /evidence="ECO:0000269|PubMed:12610651,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:19522081,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029674"
FT   VARIANT         604
FT                   /note="R -> H (in dbSNP:rs121918769)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:19589774, ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064244"
FT   VARIANT         616
FT                   /note="E -> D (found in a patient with drug-resistant
FT                   epilepsy and mild cognitive impairment; likely pathogenic;
FT                   dbSNP:rs1057519529)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078193"
FT   VARIANT         626
FT                   /note="S -> G (in DRVT; also found in a patient with
FT                   cryptogenic generalized epilepsy; dbSNP:rs121917990)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:21248271"
FT                   /id="VAR_043358"
FT   VARIANT         674
FT                   /note="D -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_073492"
FT   VARIANT         699
FT                   /note="V -> I (in dbSNP:rs1260934774)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073493"
FT   VARIANT         762
FT                   /note="N -> D (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073494"
FT   VARIANT         783
FT                   /note="L -> P (in DRVT; dbSNP:rs121917968)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064245"
FT   VARIANT         785
FT                   /note="M -> T (in DRVT; dbSNP:rs796053095)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073495"
FT   VARIANT         790
FT                   /note="Y -> C (in GEFSP2; dbSNP:rs121918782)"
FT                   /evidence="ECO:0000269|PubMed:12919402"
FT                   /id="VAR_029675"
FT   VARIANT         790
FT                   /note="Y -> F (found in patients with Panayiotopoulos
FT                   syndrome; likely pathogenic; dbSNP:rs121918782)"
FT                   /evidence="ECO:0000269|PubMed:17679682,
FT                   ECO:0000269|PubMed:19522081"
FT                   /id="VAR_073496"
FT   VARIANT         808
FT                   /note="T -> S (in ICEGTC; results in increased peak current
FT                   density and delayed slow inactivation onset; recovery from
FT                   slow inactivation is delayed; dbSNP:rs121918758)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:16210358"
FT                   /id="VAR_029676"
FT   VARIANT         812
FT                   /note="T -> I (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073497"
FT   VARIANT         812
FT                   /note="T -> R (in DRVT; dbSNP:rs121917941)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064304"
FT   VARIANT         842
FT                   /note="L -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073498"
FT   VARIANT         843
FT                   /note="S -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073499"
FT   VARIANT         846
FT                   /note="E -> K (in DRVT; dbSNP:rs121917942)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064305"
FT   VARIANT         854..855
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073500"
FT   VARIANT         859
FT                   /note="R -> C (in GEFSP2 and DRVT; causes a positive shift
FT                   in the voltage dependence of channel activation, slower
FT                   recovery from slow inactivation and lower levels of current
FT                   compared with the wild-type channel; dbSNP:rs121918784)"
FT                   /evidence="ECO:0000269|PubMed:16525050,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064306"
FT   VARIANT         859
FT                   /note="R -> H (in GEFSP2; results in impaired channel fast
FT                   inactivation and significantly increased persistent
FT                   current; dbSNP:rs398123588)"
FT                   /evidence="ECO:0000269|PubMed:21864321"
FT                   /id="VAR_073501"
FT   VARIANT         862
FT                   /note="R -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21753172"
FT                   /id="VAR_085928"
FT   VARIANT         862
FT                   /note="R -> Q (in DRVT; dbSNP:rs121918785)"
FT                   /evidence="ECO:0000269|PubMed:20110217,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064246"
FT   VARIANT         865
FT                   /note="R -> G (in DRVT; results in impaired channel fast
FT                   inactivation and significantly increased persistent
FT                   current)"
FT                   /evidence="ECO:0000269|PubMed:21864321"
FT                   /id="VAR_073502"
FT   VARIANT         875
FT                   /note="T -> K (in DRVT; dbSNP:rs121918623)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:20522430"
FT                   /id="VAR_064247"
FT   VARIANT         875
FT                   /note="T -> M (in GEFSP2 and DRVT; borderline phenotype;
FT                   dbSNP:rs121918623)"
FT                   /evidence="ECO:0000269|PubMed:10742094,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_010110"
FT   VARIANT         876
FT                   /note="L -> I (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073503"
FT   VARIANT         890
FT                   /note="L -> P (in DRVT; dbSNP:rs1553541473)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073504"
FT   VARIANT         896
FT                   /note="V -> F (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073505"
FT   VARIANT         896
FT                   /note="V -> I (in ICEGTC; dbSNP:rs745378416)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073506"
FT   VARIANT         896
FT                   /note="V -> L (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073507"
FT   VARIANT         899
FT                   /note="I -> T (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:19522081"
FT                   /id="VAR_073508"
FT   VARIANT         902
FT                   /note="F -> C (in DRVT; dbSNP:rs121918787)"
FT                   /evidence="ECO:0000269|PubMed:12083760"
FT                   /id="VAR_029677"
FT   VARIANT         924
FT                   /note="A -> T (in dbSNP:rs141950573)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073509"
FT   VARIANT         927
FT                   /note="C -> F (in DRVT; dbSNP:rs794726811)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073510"
FT   VARIANT         931
FT                   /note="R -> C (in DRVT; dbSNP:rs121918788)"
FT                   /evidence="ECO:0000269|PubMed:12083760,
FT                   ECO:0000269|PubMed:18930999"
FT                   /id="VAR_029678"
FT   VARIANT         931
FT                   /note="R -> H (in DRVT; likely pathogenic;
FT                   dbSNP:rs794726718)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:21719429"
FT                   /id="VAR_073511"
FT   VARIANT         932
FT                   /note="W -> C (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073512"
FT   VARIANT         933
FT                   /note="H -> P (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073513"
FT   VARIANT         934
FT                   /note="M -> I (in DRVT; dbSNP:rs121918774)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029679"
FT   VARIANT         935
FT                   /note="N -> H (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:18566737"
FT                   /id="VAR_073514"
FT   VARIANT         939
FT                   /note="H -> P (in DRVT; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073515"
FT   VARIANT         939
FT                   /note="H -> Q (in DRVT; results in a non-functional
FT                   channel; dbSNP:rs121918795)"
FT                   /evidence="ECO:0000269|PubMed:12754708,
FT                   ECO:0000269|PubMed:17054685"
FT                   /id="VAR_029680"
FT   VARIANT         939
FT                   /note="H -> Y (in DRVT; dbSNP:rs121918736)"
FT                   /evidence="ECO:0000269|PubMed:20431604"
FT                   /id="VAR_064248"
FT   VARIANT         940
FT                   /note="S -> F (in DRVT; dbSNP:rs1057521080)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073516"
FT   VARIANT         942
FT                   /note="L -> P (in DRVT; dbSNP:rs121917943)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064307"
FT   VARIANT         943
FT                   /note="I -> N (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073517"
FT   VARIANT         944
FT                   /note="V -> A (in DRVT and ICEGTC; dbSNP:rs121917969)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029681"
FT   VARIANT         944
FT                   /note="V -> E (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064249"
FT   VARIANT         945
FT                   /note="F -> L (in DRVT; dbSNP:rs121917970)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064250"
FT   VARIANT         946
FT                   /note="R -> C (in DRVT; loss-of-function mutation resulting
FT                   in complete absence of sodium current; dbSNP:rs121918775)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:21864321,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029682"
FT   VARIANT         946
FT                   /note="R -> H (in DRVT and GEFSP2; GEFSP2 phenotype
FT                   consists of partial epilepsy with antecedent febrile
FT                   seizures and seizure aggravation by antiepileptic drugs;
FT                   loss-of-function mutation resulting in complete absence of
FT                   sodium current; dbSNP:rs121917971)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:16713920, ECO:0000269|PubMed:19589774,
FT                   ECO:0000269|PubMed:20550552, ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:21864321, ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029683"
FT   VARIANT         946
FT                   /note="R -> S (in DRVT; dbSNP:rs121918775)"
FT                   /evidence="ECO:0000269|PubMed:15944908"
FT                   /id="VAR_057995"
FT   VARIANT         949
FT                   /note="C -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073518"
FT   VARIANT         949
FT                   /note="C -> Y (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073519"
FT   VARIANT         950
FT                   /note="G -> E (in DRVT; dbSNP:rs121917972)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064251"
FT   VARIANT         950
FT                   /note="G -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073520"
FT   VARIANT         952
FT                   /note="W -> G (in DRVT; dbSNP:rs121918737)"
FT                   /evidence="ECO:0000269|PubMed:20431604"
FT                   /id="VAR_064252"
FT   VARIANT         954
FT                   /note="E -> K (in DRVT; dbSNP:rs121918786)"
FT                   /evidence="ECO:0000269|PubMed:20110217,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064253"
FT   VARIANT         956
FT                   /note="M -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073521"
FT   VARIANT         957
FT                   /note="W -> L (in DRVT; dbSNP:rs121917917)"
FT                   /evidence="ECO:0000269|PubMed:17561957,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064308"
FT   VARIANT         959
FT                   /note="C -> R (in DRVT; results in a non-functional
FT                   channel; dbSNP:rs121918796)"
FT                   /evidence="ECO:0000269|PubMed:12754708,
FT                   ECO:0000269|PubMed:17054685"
FT                   /id="VAR_029684"
FT   VARIANT         960
FT                   /note="M -> T (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073522"
FT   VARIANT         960
FT                   /note="M -> V (in DRVT; dbSNP:rs121918750)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029685"
FT   VARIANT         973
FT                   /note="M -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073523"
FT   VARIANT         973
FT                   /note="M -> V (in GEFSP2; dbSNP:rs121917991)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_043359"
FT   VARIANT         976
FT                   /note="M -> I (in DRVT and GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:19522081,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073524"
FT   VARIANT         978
FT                   /note="I -> M (in GEFSP2; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:17927801"
FT                   /id="VAR_073525"
FT   VARIANT         979
FT                   /note="G -> R (in ICEGTC; loss-of-function mutation
FT                   resulting in absence of sodium current; dbSNP:rs121918754)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:16210358"
FT                   /id="VAR_029686"
FT   VARIANT         979
FT                   /note="G -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073526"
FT   VARIANT         982
FT                   /note="V -> L (found in a patient with acute encephalopathy
FT                   with biphasic seizures and late reduced diffusion;
FT                   uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:22309220,
FT                   ECO:0000269|PubMed:26311622"
FT                   /id="VAR_075569"
FT   VARIANT         983
FT                   /note="V -> A (in ICEGTC; reduced function; decreased peak
FT                   current density; results in a negative shift of
FT                   inactivation and positive shift of activation;
FT                   dbSNP:rs121918756)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:16210358"
FT                   /id="VAR_029687"
FT   VARIANT         985
FT                   /note="N -> I (in DRVT; dbSNP:rs121918747)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029688"
FT   VARIANT         986
FT                   /note="L -> F (in DRVT; complete loss of sodium ion
FT                   transmembrane transport; dbSNP:rs121918625)"
FT                   /evidence="ECO:0000269|PubMed:11359211,
FT                   ECO:0000269|PubMed:14672992"
FT                   /id="VAR_014268"
FT   VARIANT         986
FT                   /note="L -> P (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073527"
FT   VARIANT         987
FT                   /note="F -> L (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073528"
FT   VARIANT         993
FT                   /note="S -> R (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073529"
FT   VARIANT         998
FT                   /note="D -> G (in DRVT; dbSNP:rs1484321812)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073530"
FT   VARIANT         999..1000
FT                   /note="NL -> LIS (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073531"
FT   VARIANT         1006
FT                   /note="D -> E (found in a patient with an unclassified form
FT                   of epilepsy; likely pathogenic; dbSNP:rs375909896)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073532"
FT   VARIANT         1011
FT                   /note="N -> I (in ICEGTC; results in reduced peak current
FT                   density and hyperpolarizing shift in inactivation;
FT                   dbSNP:rs121918759)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:16210358"
FT                   /id="VAR_029689"
FT   VARIANT         1034
FT                   /note="I -> T (in dbSNP:rs121918818)"
FT                   /evidence="ECO:0000269|PubMed:12610651"
FT                   /id="VAR_029690"
FT   VARIANT         1038
FT                   /note="F -> L"
FT                   /evidence="ECO:0000269|PubMed:12610651"
FT                   /id="VAR_029691"
FT   VARIANT         1067
FT                   /note="A -> T (in dbSNP:rs2298771)"
FT                   /evidence="ECO:0000269|PubMed:11254444,
FT                   ECO:0000269|PubMed:12083760, ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:12610651, ECO:0000269|PubMed:16122630,
FT                   ECO:0000269|PubMed:19694741, ECO:0000269|PubMed:20682179,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_014269"
FT   VARIANT         1068
FT                   /note="E -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073533"
FT   VARIANT         1079
FT                   /note="V -> I"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073534"
FT   VARIANT         1109
FT                   /note="P -> T (in dbSNP:rs753452775)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073535"
FT   VARIANT         1174
FT                   /note="T -> S (in FHM3; dbSNP:rs121918799)"
FT                   /evidence="ECO:0000269|PubMed:18021921"
FT                   /id="VAR_064309"
FT   VARIANT         1204
FT                   /note="W -> R (in GEFSP2; causes hyperpolarized shifts in
FT                   the voltage dependence of activation and steady-state
FT                   inactivation; dbSNP:rs121917930)"
FT                   /evidence="ECO:0000269|PubMed:11254445,
FT                   ECO:0000269|PubMed:12535936, ECO:0000269|PubMed:17561957"
FT                   /id="VAR_014270"
FT   VARIANT         1204
FT                   /note="W -> S (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073536"
FT   VARIANT         1207
FT                   /note="L -> P (in DRVT; dbSNP:rs121917963)"
FT                   /evidence="ECO:0000269|PubMed:18413471"
FT                   /id="VAR_043360"
FT   VARIANT         1208
FT                   /note="R -> K (in DRVT; dbSNP:rs1559149025)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073537"
FT   VARIANT         1210
FT                   /note="T -> K (in DRVT; dbSNP:rs121918738)"
FT                   /evidence="ECO:0000269|PubMed:20431604"
FT                   /id="VAR_064254"
FT   VARIANT         1213
FT                   /note="R -> Q (in ICEGTC; dbSNP:rs566081370)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073538"
FT   VARIANT         1221
FT                   /note="E -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073539"
FT   VARIANT         1230
FT                   /note="L -> F (in DRVT and GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073540"
FT   VARIANT         1231
FT                   /note="S -> R (in DRVT; dbSNP:rs121918746)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029692"
FT   VARIANT         1231
FT                   /note="S -> T (in DRVT; dbSNP:rs121918800)"
FT                   /evidence="ECO:0000269|PubMed:16458823"
FT                   /id="VAR_064310"
FT   VARIANT         1233
FT                   /note="G -> R (in DRVT; dbSNP:rs121917911)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054684"
FT                   /id="VAR_029693"
FT   VARIANT         1238
FT                   /note="E -> D (in DRVT; dbSNP:rs121917973)"
FT                   /evidence="ECO:0000269|PubMed:16713920,
FT                   ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:23662938"
FT                   /id="VAR_043361"
FT   VARIANT         1239
FT                   /note="D -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073541"
FT   VARIANT         1239
FT                   /note="D -> Y (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073542"
FT   VARIANT         1245
FT                   /note="R -> Q (in DRVT; dbSNP:rs121917912)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064311"
FT   VARIANT         1249
FT                   /note="K -> N (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:19522081"
FT                   /id="VAR_073543"
FT   VARIANT         1250
FT                   /note="T -> M (in GEFSP2; dbSNP:rs140731963)"
FT                   /evidence="ECO:0000269|PubMed:19522081"
FT                   /id="VAR_073544"
FT   VARIANT         1254
FT                   /note="Y -> C (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073545"
FT   VARIANT         1255
FT                   /note="A -> D (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073546"
FT   VARIANT         1260
FT                   /note="T -> P (in DRVT; dbSNP:rs121918739)"
FT                   /evidence="ECO:0000269|PubMed:20431604"
FT                   /id="VAR_064255"
FT   VARIANT         1263
FT                   /note="F -> L (in DRVT; dbSNP:rs121918752)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029694"
FT   VARIANT         1265
FT                   /note="L -> P (in DRVT; dbSNP:rs121918794)"
FT                   /evidence="ECO:0000269|PubMed:12083760"
FT                   /id="VAR_029695"
FT   VARIANT         1266
FT                   /note="E -> A (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:21719429"
FT                   /id="VAR_073547"
FT   VARIANT         1270
FT                   /note="K -> T (in GEFSP2; dbSNP:rs121918626)"
FT                   /evidence="ECO:0000269|PubMed:11756608"
FT                   /id="VAR_014271"
FT   VARIANT         1275
FT                   /note="G -> A (found in a child with sporadic epilepsy;
FT                   uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:23647072"
FT                   /id="VAR_077831"
FT   VARIANT         1275
FT                   /note="G -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073548"
FT   VARIANT         1284..2009
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:26993267"
FT                   /id="VAR_078727"
FT   VARIANT         1284
FT                   /note="W -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073549"
FT   VARIANT         1287
FT                   /note="L -> P (in DRVT; dbSNP:rs121918740)"
FT                   /evidence="ECO:0000269|PubMed:20431604"
FT                   /id="VAR_064256"
FT   VARIANT         1288
FT                   /note="D -> N (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073550"
FT   VARIANT         1289
FT                   /note="Missing (in DRVT; results in a non-functional
FT                   channel)"
FT                   /evidence="ECO:0000269|PubMed:12083760,
FT                   ECO:0000269|PubMed:17054685, ECO:0000269|PubMed:18930999"
FT                   /id="VAR_029696"
FT   VARIANT         1308
FT                   /note="E -> D (in FEB3A; uncertain significance; also found
FT                   in patients with early infantile epileptic encephalopathy;
FT                   uncertain significance; dbSNP:rs121917910)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:19522081, ECO:0000269|PubMed:20729507,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064257"
FT   VARIANT         1309
FT                   /note="L -> F (in GEFSP2; dbSNP:rs121918801)"
FT                   /evidence="ECO:0000269|PubMed:20117752"
FT                   /id="VAR_064258"
FT   VARIANT         1316
FT                   /note="R -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073551"
FT   VARIANT         1316
FT                   /note="R -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073552"
FT   VARIANT         1320
FT                   /note="A -> V (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073553"
FT   VARIANT         1325
FT                   /note="R -> T (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073554"
FT   VARIANT         1326
FT                   /note="A -> D (found in a patient with an unclassified form
FT                   of epilepsy; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073555"
FT   VARIANT         1326
FT                   /note="A -> P (in DRVT; dbSNP:rs121918803)"
FT                   /evidence="ECO:0000269|PubMed:14504318,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_029698"
FT   VARIANT         1328
FT                   /note="S -> P (in ICEGTC and DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073556"
FT   VARIANT         1335
FT                   /note="V -> M (in DRVT; dbSNP:rs121917960)"
FT                   /evidence="ECO:0000269|PubMed:18413471,
FT                   ECO:0000269|PubMed:20431604"
FT                   /id="VAR_043362"
FT   VARIANT         1339
FT                   /note="A -> V (in DRVT; changed voltage-gated sodium
FT                   channel activity; right shift of the activation curve and
FT                   slight left shift of the inactivation curve;
FT                   dbSNP:rs794726789)"
FT                   /evidence="ECO:0000269|PubMed:22092154,
FT                   ECO:0000269|PubMed:23195492, ECO:0000269|PubMed:33712547"
FT                   /id="VAR_073557"
FT   VARIANT         1344
FT                   /note="I -> M (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073558"
FT   VARIANT         1345
FT                   /note="P -> L (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:26993267"
FT                   /id="VAR_078728"
FT   VARIANT         1345
FT                   /note="P -> S (in DEE6B)"
FT                   /evidence="ECO:0000269|PubMed:28794249"
FT                   /id="VAR_085929"
FT   VARIANT         1350
FT                   /note="V -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073559"
FT   VARIANT         1353
FT                   /note="V -> L (in GEFSP2; complete loss of sodium ion
FT                   transmembrane transport; dbSNP:rs121917954)"
FT                   /evidence="ECO:0000269|PubMed:11254444,
FT                   ECO:0000269|PubMed:14672992"
FT                   /id="VAR_014272"
FT   VARIANT         1355
FT                   /note="L -> P (in DRVT; dbSNP:rs121918776)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029697"
FT   VARIANT         1357
FT                   /note="F -> L (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073560"
FT   VARIANT         1358
FT                   /note="W -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073561"
FT   VARIANT         1358
FT                   /note="W -> S (in DRVT; dbSNP:rs121917961)"
FT                   /evidence="ECO:0000269|PubMed:18413471"
FT                   /id="VAR_043363"
FT   VARIANT         1366
FT                   /note="V -> I (in GEFSP2 and ICEGTC; dbSNP:rs121918805)"
FT                   /evidence="ECO:0000269|PubMed:17507202"
FT                   /id="VAR_043364"
FT   VARIANT         1367
FT                   /note="N -> K (in DRVT; dbSNP:rs121918760)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:20522430"
FT                   /id="VAR_064259"
FT   VARIANT         1370
FT                   /note="A -> P (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073562"
FT   VARIANT         1376
FT                   /note="C -> R (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073563"
FT   VARIANT         1378
FT                   /note="N -> H (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073564"
FT   VARIANT         1378
FT                   /note="N -> T (in DRVT; dbSNP:rs1131691775)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073565"
FT   VARIANT         1385
FT                   /note="F -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073566"
FT   VARIANT         1390
FT                   /note="V -> M (in DRVT; some patients have a borderline
FT                   DRVT phenotype; dbSNP:rs121917986)"
FT                   /evidence="ECO:0000269|PubMed:12083760,
FT                   ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:20431604"
FT                   /id="VAR_029699"
FT   VARIANT         1391
FT                   /note="N -> S (in DRVT; dbSNP:rs1553525062)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073567"
FT   VARIANT         1393
FT                   /note="H -> P (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:17129991"
FT                   /id="VAR_073568"
FT   VARIANT         1394
FT                   /note="T -> I (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073569"
FT   VARIANT         1396
FT                   /note="C -> G (in DRVT; some patients have a borderline
FT                   DRVT phenotype; dbSNP:rs121917987)"
FT                   /evidence="ECO:0000269|PubMed:16713920,
FT                   ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064260"
FT   VARIANT         1396
FT                   /note="C -> Y (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073570"
FT   VARIANT         1414
FT                   /note="N -> D (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073571"
FT   VARIANT         1414
FT                   /note="N -> Y (in DRVT; dbSNP:rs121917925)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064312"
FT   VARIANT         1416
FT                   /note="D -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073572"
FT   VARIANT         1417
FT                   /note="N -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073573"
FT   VARIANT         1418
FT                   /note="V -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073574"
FT   VARIANT         1422
FT                   /note="Y -> C (in DRVT; dbSNP:rs121917913)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064313"
FT   VARIANT         1423
FT                   /note="L -> F (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073575"
FT   VARIANT         1426
FT                   /note="L -> R (in DRVT; dbSNP:rs121917944)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064314"
FT   VARIANT         1427
FT                   /note="Q -> P (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073576"
FT   VARIANT         1428
FT                   /note="V -> A (in GEFSP2; dbSNP:rs121918627)"
FT                   /evidence="ECO:0000269|PubMed:11524484"
FT                   /id="VAR_029700"
FT   VARIANT         1429
FT                   /note="A -> D (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073577"
FT   VARIANT         1429
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073578"
FT   VARIANT         1431
FT                   /note="F -> I (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073579"
FT   VARIANT         1433
FT                   /note="G -> E (in DRVT; dbSNP:rs121918741)"
FT                   /evidence="ECO:0000269|PubMed:20431604"
FT                   /id="VAR_064261"
FT   VARIANT         1433
FT                   /note="G -> R (in DRVT; dbSNP:rs121917908)"
FT                   /evidence="ECO:0000269|PubMed:20729507"
FT                   /id="VAR_064262"
FT   VARIANT         1433
FT                   /note="G -> V (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073580"
FT   VARIANT         1434
FT                   /note="W -> R (in DRVT; dbSNP:rs121918789)"
FT                   /evidence="ECO:0000269|PubMed:12083760,
FT                   ECO:0000269|PubMed:12754708"
FT                   /id="VAR_029701"
FT   VARIANT         1437
FT                   /note="I -> M (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073581"
FT   VARIANT         1440
FT                   /note="A -> V (found in a patient with autism; uncertain
FT                   significance; dbSNP:rs1559122124)"
FT                   /evidence="ECO:0000269|PubMed:26637798"
FT                   /id="VAR_078729"
FT   VARIANT         1441
FT                   /note="A -> P (in DRVT; dbSNP:rs121917974)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_064348"
FT   VARIANT         1450
FT                   /note="Q -> K (in DRVT; dbSNP:rs121918806)"
FT                   /evidence="ECO:0000269|PubMed:19589774,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064263"
FT   VARIANT         1450
FT                   /note="Q -> R (in DRVT; dbSNP:rs121918790)"
FT                   /evidence="ECO:0000269|PubMed:12083760"
FT                   /id="VAR_029702"
FT   VARIANT         1451
FT                   /note="P -> L (in DRVT; dbSNP:rs121917945)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064315"
FT   VARIANT         1451
FT                   /note="P -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073582"
FT   VARIANT         1453
FT                   /note="Y -> C (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073583"
FT   VARIANT         1454
FT                   /note="E -> K (in DRVT; dbSNP:rs1553522472)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073584"
FT   VARIANT         1461
FT                   /note="L -> I (in DRVT; dbSNP:rs121918772)"
FT                   /evidence="ECO:0000269|PubMed:12821740"
FT                   /id="VAR_029703"
FT   VARIANT         1462
FT                   /note="Y -> C (in DRVT; dbSNP:rs121917962)"
FT                   /evidence="ECO:0000269|PubMed:18413471"
FT                   /id="VAR_043365"
FT   VARIANT         1462
FT                   /note="Y -> H (in DRVT and ICEGTC; borderline DRVT
FT                   phenotype; dbSNP:rs1559119345)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:21719429, ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073585"
FT   VARIANT         1463
FT                   /note="F -> S (in DRVT; dbSNP:rs121917946)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054684"
FT                   /id="VAR_029704"
FT   VARIANT         1470
FT                   /note="G -> W (in DRVT; dbSNP:rs121917924)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064316"
FT   VARIANT         1472
FT                   /note="F -> S (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073586"
FT   VARIANT         1473
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073587"
FT   VARIANT         1475
FT                   /note="L -> S (in DRVT; dbSNP:rs121917947)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064317"
FT   VARIANT         1476
FT                   /note="N -> K (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073588"
FT   VARIANT         1480
FT                   /note="G -> V (found in a patient with myoclonic astatic
FT                   epilepsy; likely pathogenic; dbSNP:rs121917996)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_043366"
FT   VARIANT         1483
FT                   /note="I -> M (found in a patient with an unclassified form
FT                   of epilepsy; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073589"
FT   VARIANT         1483
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073590"
FT   VARIANT         1484
FT                   /note="D -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073591"
FT   VARIANT         1485
FT                   /note="N -> Y (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073592"
FT   VARIANT         1489
FT                   /note="Q -> H (in FHM3; dbSNP:rs121918633)"
FT                   /evidence="ECO:0000269|PubMed:19332696"
FT                   /id="VAR_057996"
FT   VARIANT         1489
FT                   /note="Q -> K (in FHM3; dbSNP:rs121918628)"
FT                   /evidence="ECO:0000269|PubMed:16054936"
FT                   /id="VAR_025281"
FT   VARIANT         1499
FT                   /note="F -> L (in FHM3; changed voltage-gated sodium
FT                   channel activity; right shift of the inactivation curve
FT                   without major impact on activation; dbSNP:rs121918632)"
FT                   /evidence="ECO:0000269|PubMed:19332696,
FT                   ECO:0000269|PubMed:33712547"
FT                   /id="VAR_057997"
FT   VARIANT         1503
FT                   /note="E -> K (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:19783390,
FT                   ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073593"
FT   VARIANT         1503
FT                   /note="Missing (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073594"
FT   VARIANT         1511
FT                   /note="M -> K (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073595"
FT   VARIANT         1514
FT                   /note="L -> S (in DRVT; dbSNP:rs121918764)"
FT                   /evidence="ECO:0000269|PubMed:20522430"
FT                   /id="VAR_064264"
FT   VARIANT         1523
FT                   /note="I -> T (in DRVT; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:21719429"
FT                   /id="VAR_090163"
FT   VARIANT         1538
FT                   /note="V -> I (in DRVT; dbSNP:rs780360360)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073596"
FT   VARIANT         1543
FT                   /note="F -> S (in a patient with cryptogenic focal
FT                   epilepsy; dbSNP:rs121917992)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_043367"
FT   VARIANT         1544
FT                   /note="D -> A (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073597"
FT   VARIANT         1544
FT                   /note="D -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073598"
FT   VARIANT         1545
FT                   /note="I -> V (in DRVT; dbSNP:rs121917975)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:19589774, ECO:0000269|PubMed:23195492"
FT                   /id="VAR_064265"
FT   VARIANT         1555
FT                   /note="M -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073599"
FT   VARIANT         1559
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:14738421"
FT                   /id="VAR_029705"
FT   VARIANT         1561
FT                   /note="E -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073600"
FT   VARIANT         1575
FT                   /note="R -> C (found in patients with Dravet syndrome;
FT                   uncertain significance; found in a patient with acute
FT                   necrotizing encephalopathy; uncertain significance; also
FT                   found in a patient with acute encephalopathy with biphasic
FT                   seizures and late reduced diffusion; uncertain
FT                   significance; dbSNP:rs121918807)"
FT                   /evidence="ECO:0000269|PubMed:18031552,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:22309220,
FT                   ECO:0000269|PubMed:23195492, ECO:0000269|PubMed:26311622"
FT                   /id="VAR_064318"
FT   VARIANT         1579
FT                   /note="V -> E (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073601"
FT   VARIANT         1586
FT                   /note="G -> E (in DRVT; dbSNP:rs121918742)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:20431604, ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064266"
FT   VARIANT         1588
FT                   /note="C -> R (in DRVT; dbSNP:rs121917919)"
FT                   /evidence="ECO:0000269|PubMed:17561957,
FT                   ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:25818041"
FT                   /id="VAR_064319"
FT   VARIANT         1592
FT                   /note="L -> H (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073602"
FT   VARIANT         1592
FT                   /note="L -> P (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073603"
FT   VARIANT         1596
FT                   /note="R -> C (in DRVT; also found in a patient with
FT                   cryptogenic focal epilepsy; affects voltage-gated sodium
FT                   channel activity resulting in reduced current amplitude and
FT                   a hyperpolarizing shift of the inactivation curve with no
FT                   changes in the kinetics of recovery from inactivation;
FT                   dbSNP:rs121917993)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:38339022"
FT                   /id="VAR_043368"
FT   VARIANT         1596
FT                   /note="R -> H (in GEFSP2; dbSNP:rs575368466)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073604"
FT   VARIANT         1596
FT                   /note="R -> L (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073605"
FT   VARIANT         1605
FT                   /note="N -> I (in DRVT; dbSNP:rs1057519533)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078194"
FT   VARIANT         1605
FT                   /note="N -> S (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073606"
FT   VARIANT         1608
FT                   /note="D -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073607"
FT   VARIANT         1608
FT                   /note="D -> Y (in DRVT; dbSNP:rs121917915)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064320"
FT   VARIANT         1611
FT                   /note="V -> F (in ICEGTC; results in greater levels of
FT                   persistent non-inactivating current compared to wild-type;
FT                   dbSNP:rs121918630)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:16210358"
FT                   /id="VAR_029706"
FT   VARIANT         1612
FT                   /note="V -> I (in DRVT; dbSNP:rs121918808)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:19563458, ECO:0000269|PubMed:20452746"
FT                   /id="VAR_064267"
FT   VARIANT         1619
FT                   /note="M -> V (in ICEGTC; dbSNP:rs373967247)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073608"
FT   VARIANT         1630
FT                   /note="V -> L (in DRVT; borderline phenotype in some
FT                   patients; dbSNP:rs121917914)"
FT                   /evidence="ECO:0000269|PubMed:22092154,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073609"
FT   VARIANT         1630
FT                   /note="V -> M (in DRVT; dbSNP:rs121917914)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064321"
FT   VARIANT         1632
FT                   /note="P -> S (in ICEGTC; results in greater levels of
FT                   persistent non-inactivating current compared to wild-type;
FT                   dbSNP:rs121918755)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:16210358"
FT                   /id="VAR_029707"
FT   VARIANT         1636
FT                   /note="R -> Q (found in a patient with Lennon-Gastaut
FT                   syndrome; likely pathogenic; dbSNP:rs121917995)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:19589774"
FT                   /id="VAR_043369"
FT   VARIANT         1637
FT                   /note="V -> E (in DRVT; also found in a child with febrile
FT                   status epilepticus who developed liver failure;
FT                   dbSNP:rs121918810)"
FT                   /evidence="ECO:0000269|PubMed:20392657,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064268"
FT   VARIANT         1638
FT                   /note="I -> N (in DRVT; dbSNP:rs1057521079)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073610"
FT   VARIANT         1638
FT                   /note="I -> T (in DRVT; also found in a patient with an
FT                   unclassified form of epilepsy)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:21719429"
FT                   /id="VAR_073611"
FT   VARIANT         1639
FT                   /note="R -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073612"
FT   VARIANT         1642
FT                   /note="R -> S (in DRVT; dbSNP:rs1131691581)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073613"
FT   VARIANT         1645
FT                   /note="R -> Q (in DRVT; dbSNP:rs121917976)"
FT                   /evidence="ECO:0000269|PubMed:16713920,
FT                   ECO:0000269|PubMed:17347258, ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064269"
FT   VARIANT         1648
FT                   /note="R -> C (in DRVT; dbSNP:rs121918791)"
FT                   /evidence="ECO:0000269|PubMed:12083760,
FT                   ECO:0000269|PubMed:19522081, ECO:0000269|PubMed:21248271"
FT                   /id="VAR_029708"
FT   VARIANT         1648
FT                   /note="R -> H (in GEFSP2 and DRVT; dbSNP:rs121918622)"
FT                   /evidence="ECO:0000269|PubMed:10742094,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:20522430"
FT                   /id="VAR_010111"
FT   VARIANT         1649
FT                   /note="L -> Q (in FHM3)"
FT                   /evidence="ECO:0000269|PubMed:17397047"
FT                   /id="VAR_064322"
FT   VARIANT         1653
FT                   /note="A -> E (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073614"
FT   VARIANT         1656
FT                   /note="I -> M (in GEFSP2; changed voltage-gated sodium
FT                   channel activity; exhibits a depolarizing shift in the
FT                   voltage dependence of activation; dbSNP:rs121917955)"
FT                   /evidence="ECO:0000269|PubMed:11254444,
FT                   ECO:0000269|PubMed:14672992"
FT                   /id="VAR_014273"
FT   VARIANT         1657
FT                   /note="R -> C (in GEFSP2; changed voltage-gated sodium
FT                   channel activity; exhibits a depolarizing shift in the
FT                   voltage dependence of activation; shows a 50% reduction in
FT                   current density and accelerates recovery from slow
FT                   inactivation; dbSNP:rs121918811)"
FT                   /evidence="ECO:0000269|PubMed:14672992"
FT                   /id="VAR_029709"
FT   VARIANT         1657
FT                   /note="R -> H (found in a patient with cryptogenic focal
FT                   epilepsy; likely pathogenic; dbSNP:rs121917994)"
FT                   /evidence="ECO:0000269|PubMed:17347258,
FT                   ECO:0000269|PubMed:19589774"
FT                   /id="VAR_043370"
FT   VARIANT         1658
FT                   /note="T -> M (in DRVT; dbSNP:rs121917922)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:20522430"
FT                   /id="VAR_064270"
FT   VARIANT         1658
FT                   /note="T -> R (in DRVT; changed voltage-gated sodium
FT                   channel activity; inactivation curve is shifted toward the
FT                   negative potential; dbSNP:rs121917922)"
FT                   /evidence="ECO:0000269|PubMed:17561957,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:33712547"
FT                   /id="VAR_064323"
FT   VARIANT         1660
FT                   /note="L -> P (in DRVT; dbSNP:rs1131691675)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073615"
FT   VARIANT         1661
FT                   /note="F -> S (in DRVT; dbSNP:rs121918797)"
FT                   /evidence="ECO:0000269|PubMed:12754708"
FT                   /id="VAR_029710"
FT   VARIANT         1662
FT                   /note="A -> V (in DRVT; borderline phenotype;
FT                   dbSNP:rs794726839)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073616"
FT   VARIANT         1664
FT                   /note="M -> K (in DRVT; dbSNP:rs121918765)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:20522430"
FT                   /id="VAR_064271"
FT   VARIANT         1667
FT                   /note="L -> P (in DRVT; dbSNP:rs1131691774)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073617"
FT   VARIANT         1668
FT                   /note="P -> A (in DRVT; dbSNP:rs121917948)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054684"
FT                   /id="VAR_029711"
FT   VARIANT         1668
FT                   /note="P -> L (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073618"
FT   VARIANT         1669
FT                   /note="A -> E (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21555645"
FT                   /id="VAR_085930"
FT   VARIANT         1672
FT                   /note="N -> I (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073619"
FT   VARIANT         1673
FT                   /note="I -> T (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073620"
FT   VARIANT         1674
FT                   /note="G -> R (in DRVT; dbSNP:rs121918792)"
FT                   /evidence="ECO:0000269|PubMed:12083760"
FT                   /id="VAR_029712"
FT   VARIANT         1674
FT                   /note="G -> S (found in a patient acute encephalopathy with
FT                   biphasic seizures and late reduced diffusion; uncertain
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:26311622"
FT                   /id="VAR_075570"
FT   VARIANT         1675
FT                   /note="L -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073621"
FT   VARIANT         1677
FT                   /note="L -> F (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073622"
FT   VARIANT         1683
FT                   /note="I -> F (found in a patient with an unclassified form
FT                   of epilepsy; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073623"
FT   VARIANT         1683
FT                   /note="I -> T (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073624"
FT   VARIANT         1684
FT                   /note="Y -> D (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073625"
FT   VARIANT         1684
FT                   /note="Y -> S (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073626"
FT   VARIANT         1685
FT                   /note="A -> D (in DRVT; dbSNP:rs121918744)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029714"
FT   VARIANT         1685
FT                   /note="A -> V (in GEFSP2; complete loss of sodium ion
FT                   transmembrane transport; dbSNP:rs121918744)"
FT                   /evidence="ECO:0000269|PubMed:11524484,
FT                   ECO:0000269|PubMed:14672992"
FT                   /id="VAR_029715"
FT   VARIANT         1687
FT                   /note="F -> S (in GEFSP2; dbSNP:rs121917932)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064324"
FT   VARIANT         1688
FT                   /note="G -> W (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073627"
FT   VARIANT         1692
FT                   /note="F -> S (in DRVT; dbSNP:rs121918778)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029716"
FT   VARIANT         1694
FT                   /note="Y -> C (in DRVT; dbSNP:rs121918777)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029713"
FT   VARIANT         1707
FT                   /note="F -> V (in DRVT; dbSNP:rs121917977)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_064349"
FT   VARIANT         1709
FT                   /note="T -> I (in ICEGTC; loss-of-function mutation
FT                   resulting in absence of sodium current; dbSNP:rs121918629)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:16210358"
FT                   /id="VAR_029717"
FT   VARIANT         1713
FT                   /note="S -> N (in DRVT; dbSNP:rs121918816)"
FT                   /evidence="ECO:0000269|PubMed:16122630"
FT                   /id="VAR_064325"
FT   VARIANT         1714
FT                   /note="M -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073628"
FT   VARIANT         1714
FT                   /note="M -> R (in DRVT; dbSNP:rs121917949)"
FT                   /evidence="ECO:0000269|PubMed:17054684,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064326"
FT   VARIANT         1716
FT                   /note="C -> R (in DRVT; dbSNP:rs121917926)"
FT                   /evidence="ECO:0000269|PubMed:17561957"
FT                   /id="VAR_064327"
FT   VARIANT         1721
FT                   /note="T -> R (in DRVT; dbSNP:rs121917978)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_064350"
FT   VARIANT         1724
FT                   /note="A -> P (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073629"
FT   VARIANT         1725
FT                   /note="G -> C (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073630"
FT   VARIANT         1726
FT                   /note="W -> R (in DRVT; dbSNP:rs121917979)"
FT                   /evidence="ECO:0000269|PubMed:19589774"
FT                   /id="VAR_064272"
FT   VARIANT         1727
FT                   /note="D -> G (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073631"
FT   VARIANT         1739
FT                   /note="P -> L (in GEFSP2)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073632"
FT   VARIANT         1741
FT                   /note="C -> R (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073633"
FT   VARIANT         1742
FT                   /note="D -> G (in GEFSP2; dbSNP:rs121918812)"
FT                   /evidence="ECO:0000269|PubMed:15694566"
FT                   /id="VAR_057998"
FT   VARIANT         1749
FT                   /note="G -> E (in DRVT; dbSNP:rs121918798)"
FT                   /evidence="ECO:0000269|PubMed:12754708"
FT                   /id="VAR_029718"
FT   VARIANT         1756
FT                   /note="C -> G (in DRVT; dbSNP:rs121918809)"
FT                   /evidence="ECO:0000269|PubMed:19563458,
FT                   ECO:0000269|PubMed:20452746"
FT                   /id="VAR_064273"
FT   VARIANT         1762
FT                   /note="G -> E (in DRVT; dbSNP:rs121917950)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064328"
FT   VARIANT         1763
FT                   /note="I -> N (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073634"
FT   VARIANT         1765
FT                   /note="F -> L (in GEFSP2; disease phenotype consists of
FT                   partial epilepsy with antecedent febrile seizures and
FT                   seizure aggravation by antiepileptic drugs;
FT                   loss-of-function mutation resulting in complete absence of
FT                   sodium current)"
FT                   /evidence="ECO:0000269|PubMed:20550552"
FT                   /id="VAR_073635"
FT   VARIANT         1766
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029719"
FT   VARIANT         1770
FT                   /note="I -> F (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073636"
FT   VARIANT         1770
FT                   /note="I -> N (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073637"
FT   VARIANT         1770
FT                   /note="I -> T (in DRVT; borderline phenotype)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073638"
FT   VARIANT         1771
FT                   /note="I -> F (in DRVT; borderline phenotype; also found in
FT                   a patient with focal epilepsy)"
FT                   /evidence="ECO:0000269|PubMed:18330841,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073639"
FT   VARIANT         1771
FT                   /note="I -> N (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073640"
FT   VARIANT         1773
FT                   /note="S -> F (in DRVT; dbSNP:rs121917951)"
FT                   /evidence="ECO:0000269|PubMed:17054684"
FT                   /id="VAR_064329"
FT   VARIANT         1780
FT                   /note="M -> T (in DRVT; dbSNP:rs121917952)"
FT                   /evidence="ECO:0000269|PubMed:12821740,
FT                   ECO:0000269|PubMed:17054684, ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_029720"
FT   VARIANT         1781
FT                   /note="Y -> C (in DRVT and ICEGTC; dbSNP:rs121918779)"
FT                   /evidence="ECO:0000269|PubMed:14738421,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_029721"
FT   VARIANT         1781
FT                   /note="Y -> H (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073641"
FT   VARIANT         1782
FT                   /note="I -> M (in DRVT; dbSNP:rs121918763)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:20522430"
FT                   /id="VAR_064274"
FT   VARIANT         1782
FT                   /note="I -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073642"
FT   VARIANT         1783
FT                   /note="A -> T (in DRVT; dbSNP:rs121917980)"
FT                   /evidence="ECO:0000269|PubMed:18930999,
FT                   ECO:0000269|PubMed:19589774, ECO:0000269|PubMed:20431604,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_064275"
FT   VARIANT         1783
FT                   /note="A -> V (in DRVT; dbSNP:rs121917921)"
FT                   /evidence="ECO:0000269|PubMed:17561957,
FT                   ECO:0000269|PubMed:18930999, ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:23195492"
FT                   /id="VAR_064345"
FT   VARIANT         1787
FT                   /note="E -> K (in DRVT; dbSNP:rs121917916)"
FT                   /evidence="ECO:0000269|PubMed:17561957,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_064330"
FT   VARIANT         1788
FT                   /note="N -> K (in DRVT; uncertain significance;
FT                   dbSNP:rs1381184010)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073643"
FT   VARIANT         1792
FT                   /note="A -> T (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073644"
FT   VARIANT         1795
FT                   /note="E -> K (in GEFSP2; dbSNP:rs121918813)"
FT                   /evidence="ECO:0000269|PubMed:20600615"
FT                   /id="VAR_064276"
FT   VARIANT         1807..1810
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029722"
FT   VARIANT         1808
FT                   /note="F -> I (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073645"
FT   VARIANT         1808
FT                   /note="F -> L (in ICEGTC; results in decreased peak current
FT                   density but significantly greater levels of persistent
FT                   non-inactivating current compared to wild-type channel;
FT                   dbSNP:rs121918757)"
FT                   /evidence="ECO:0000269|PubMed:12566275,
FT                   ECO:0000269|PubMed:16210358"
FT                   /id="VAR_029723"
FT   VARIANT         1812..1815
FT                   /note="WEKF -> C (in DRVT)"
FT                   /id="VAR_029725"
FT   VARIANT         1812
FT                   /note="W -> G (in DRVT; dbSNP:rs121918751)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029724"
FT   VARIANT         1812
FT                   /note="W -> S (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073646"
FT   VARIANT         1813..1815
FT                   /note="Missing (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073647"
FT   VARIANT         1831
FT                   /note="F -> S (in DRVT; dbSNP:rs121918748)"
FT                   /evidence="ECO:0000269|PubMed:12566275"
FT                   /id="VAR_029726"
FT   VARIANT         1832
FT                   /note="A -> P (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073648"
FT   VARIANT         1835
FT                   /note="L -> F (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:18930999"
FT                   /id="VAR_073649"
FT   VARIANT         1852
FT                   /note="M -> K (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073650"
FT   VARIANT         1852
FT                   /note="M -> T (in GEFSP2; loss of localization to the
FT                   plasma membrane; no effect on voltage-gated sodium channel
FT                   activity; no effect on interaction with SCN1B;
FT                   dbSNP:rs121918783)"
FT                   /evidence="ECO:0000269|PubMed:12919402,
FT                   ECO:0000269|PubMed:17928445, ECO:0000269|PubMed:33712547"
FT                   /id="VAR_029727"
FT   VARIANT         1855
FT                   /note="P -> L (in DRVT; dbSNP:rs1057517958)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073651"
FT   VARIANT         1857
FT                   /note="V -> L (in GEFSP2; dbSNP:rs121918814)"
FT                   /evidence="ECO:0000269|PubMed:15715999"
FT                   /id="VAR_057999"
FT   VARIANT         1861
FT                   /note="R -> W (in ICEGTC)"
FT                   /evidence="ECO:0000269|PubMed:23195492"
FT                   /id="VAR_073652"
FT   VARIANT         1866
FT                   /note="D -> Y (in GEFSP2; causes a positive shift in the
FT                   voltage dependence of sodium channel fast inactivation;
FT                   causes an increase in the magnitude of the persistent
FT                   current; causes delay in the kinetics of inactivation and
FT                   significantly reduces interaction with SCN1B;
FT                   dbSNP:rs121918815)"
FT                   /evidence="ECO:0000269|PubMed:15525788"
FT                   /id="VAR_058000"
FT   VARIANT         1867
FT                   /note="I -> T (in GEFSP2; dbSNP:rs1131691773)"
FT                   /evidence="ECO:0000269|PubMed:18251839,
FT                   ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073653"
FT   VARIANT         1880
FT                   /note="G -> E (in DRVT; dbSNP:rs201905405)"
FT                   /evidence="ECO:0000269|PubMed:21248271,
FT                   ECO:0000269|PubMed:21719429"
FT                   /id="VAR_073654"
FT   VARIANT         1881
FT                   /note="E -> D (in DRVT; dbSNP:rs121918804)"
FT                   /evidence="ECO:0000269|PubMed:14504318"
FT                   /id="VAR_029728"
FT   VARIANT         1909
FT                   /note="T -> I (in DRVT; functional channel displaying
FT                   decreased peak current densities but increased persistent
FT                   current; dbSNP:rs121918793)"
FT                   /evidence="ECO:0000269|PubMed:12083760,
FT                   ECO:0000269|PubMed:17054685"
FT                   /id="VAR_029729"
FT   VARIANT         1909
FT                   /note="Missing (in DRVT; dbSNP:rs1553519902)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073655"
FT   VARIANT         1922
FT                   /note="I -> T (in DRVT; dbSNP:rs121917981)"
FT                   /evidence="ECO:0000269|PubMed:17347258"
FT                   /id="VAR_064351"
FT   VARIANT         1927
FT                   /note="R -> IIQ (in DRVT)"
FT                   /evidence="ECO:0000269|PubMed:21248271"
FT                   /id="VAR_073656"
FT   VARIANT         1928
FT                   /note="R -> G (in dbSNP:rs121917956)"
FT                   /evidence="ECO:0000269|PubMed:11254444,
FT                   ECO:0000269|PubMed:18413471, ECO:0000269|PubMed:18930999"
FT                   /id="VAR_043371"
FT   VARIANT         1955
FT                   /note="I -> T (in dbSNP:rs35735053)"
FT                   /evidence="ECO:0000269|PubMed:12610651"
FT                   /id="VAR_029730"
FT   VARIANT         1957
FT                   /note="E -> G (in infantile spasms; dbSNP:rs121918802)"
FT                   /evidence="ECO:0000269|PubMed:14504318"
FT                   /id="VAR_029731"
FT   VARIANT         1977
FT                   /note="M -> L (found in a patient with febrile seizures and
FT                   non-specific acute encephalopathy; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:22309220"
FT                   /id="VAR_075571"
FT   VARIANT         1988
FT                   /note="R -> W (found in a patient with epilepsy-aphasia and
FT                   febrile seizures plus; uncertain significance;
FT                   dbSNP:rs756519197)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078611"
FT   CONFLICT        670
FT                   /note="E -> G (in Ref. 2; AAK00217)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        746
FT                   /note="L -> S (in Ref. 2; AAK00217)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        930
FT                   /note="P -> PQ (in Ref. 2; AAK00217)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1158..1161
FT                   /note="DIGA -> GHRR (in Ref. 2; AAK00217)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1537
FT                   /note="F -> L (in Ref. 7; CAA46439/M91803)"
FT                   /evidence="ECO:0000305"
FT   HELIX           117..125
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           128..145
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           152..176
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           189..204
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          205..207
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           215..225
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           226..229
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           234..245
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           248..268
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            269..271
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           272..274
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          315..318
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          322..324
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            359..362
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          365..367
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           369..379
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           384..395
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           397..399
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           400..438
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           750..762
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            763..766
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           770..786
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           794..818
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            819..821
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           832..847
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           856..871
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           874..885
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            886..890
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           891..911
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           915..918
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           920..922
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          925..927
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           937..949
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           954..963
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           965..994
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1204..1215
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1218..1233
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            1234..1237
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1240..1244
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          1246..1248
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1249..1280
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1283..1304
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1312..1315
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1316..1326
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            1327..1329
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1331..1341
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1344..1368
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          1369..1372
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          1375..1378
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            1379..1381
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            1387..1389
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1393..1401
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          1406..1409
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          1412..1417
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1418..1430
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1434..1442
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1457..1459
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1460..1469
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            1470..1472
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1473..1493
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1504..1514
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1530..1539
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1541..1559
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1567..1594
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1603..1620
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            1622..1627
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1632..1638
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1639..1642
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1643..1646
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1647..1651
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1656..1691
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            1692..1694
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          1703..1709
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1710..1721
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   TURN            1722..1725
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1726..1733
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   STRAND          1748..1751
FT                   /evidence="ECO:0007829|PDB:7DTD"
FT   HELIX           1759..1792
FT                   /evidence="ECO:0007829|PDB:7DTD"
SQ   SEQUENCE   2009 AA;  228972 MW;  0593A6730F33C9A2 CRC64;
     MEQTVLVPPG PDSFNFFTRE SLAAIERRIA EEKAKNPKPD KKDDDENGPK PNSDLEAGKN
     LPFIYGDIPP EMVSEPLEDL DPYYINKKTF IVLNKGKAIF RFSATSALYI LTPFNPLRKI
     AIKILVHSLF SMLIMCTILT NCVFMTMSNP PDWTKNVEYT FTGIYTFESL IKIIARGFCL
     EDFTFLRDPW NWLDFTVITF AYVTEFVDLG NVSALRTFRV LRALKTISVI PGLKTIVGAL
     IQSVKKLSDV MILTVFCLSV FALIGLQLFM GNLRNKCIQW PPTNASLEEH SIEKNITVNY
     NGTLINETVF EFDWKSYIQD SRYHYFLEGF LDALLCGNSS DAGQCPEGYM CVKAGRNPNY
     GYTSFDTFSW AFLSLFRLMT QDFWENLYQL TLRAAGKTYM IFFVLVIFLG SFYLINLILA
     VVAMAYEEQN QATLEEAEQK EAEFQQMIEQ LKKQQEAAQQ AATATASEHS REPSAAGRLS
     DSSSEASKLS SKSAKERRNR RKKRKQKEQS GGEEKDEDEF QKSESEDSIR RKGFRFSIEG
     NRLTYEKRYS SPHQSLLSIR GSLFSPRRNS RTSLFSFRGR AKDVGSENDF ADDEHSTFED
     NESRRDSLFV PRRHGERRNS NLSQTSRSSR MLAVFPANGK MHSTVDCNGV VSLVGGPSVP
     TSPVGQLLPE VIIDKPATDD NGTTTETEMR KRRSSSFHVS MDFLEDPSQR QRAMSIASIL
     TNTVEELEES RQKCPPCWYK FSNIFLIWDC SPYWLKVKHV VNLVVMDPFV DLAITICIVL
     NTLFMAMEHY PMTDHFNNVL TVGNLVFTGI FTAEMFLKII AMDPYYYFQE GWNIFDGFIV
     TLSLVELGLA NVEGLSVLRS FRLLRVFKLA KSWPTLNMLI KIIGNSVGAL GNLTLVLAII
     VFIFAVVGMQ LFGKSYKDCV CKIASDCQLP RWHMNDFFHS FLIVFRVLCG EWIETMWDCM
     EVAGQAMCLT VFMMVMVIGN LVVLNLFLAL LLSSFSADNL AATDDDNEMN NLQIAVDRMH
     KGVAYVKRKI YEFIQQSFIR KQKILDEIKP LDDLNNKKDS CMSNHTAEIG KDLDYLKDVN
     GTTSGIGTGS SVEKYIIDES DYMSFINNPS LTVTVPIAVG ESDFENLNTE DFSSESDLEE
     SKEKLNESSS SSEGSTVDIG APVEEQPVVE PEETLEPEAC FTEGCVQRFK CCQINVEEGR
     GKQWWNLRRT CFRIVEHNWF ETFIVFMILL SSGALAFEDI YIDQRKTIKT MLEYADKVFT
     YIFILEMLLK WVAYGYQTYF TNAWCWLDFL IVDVSLVSLT ANALGYSELG AIKSLRTLRA
     LRPLRALSRF EGMRVVVNAL LGAIPSIMNV LLVCLIFWLI FSIMGVNLFA GKFYHCINTT
     TGDRFDIEDV NNHTDCLKLI ERNETARWKN VKVNFDNVGF GYLSLLQVAT FKGWMDIMYA
     AVDSRNVELQ PKYEESLYMY LYFVIFIIFG SFFTLNLFIG VIIDNFNQQK KKFGGQDIFM
     TEEQKKYYNA MKKLGSKKPQ KPIPRPGNKF QGMVFDFVTR QVFDISIMIL ICLNMVTMMV
     ETDDQSEYVT TILSRINLVF IVLFTGECVL KLISLRHYYF TIGWNIFDFV VVILSIVGMF
     LAELIEKYFV SPTLFRVIRL ARIGRILRLI KGAKGIRTLL FALMMSLPAL FNIGLLLFLV
     MFIYAIFGMS NFAYVKREVG IDDMFNFETF GNSMICLFQI TTSAGWDGLL APILNSKPPD
     CDPNKVNPGS SVKGDCGNPS VGIFFFVSYI IISFLVVVNM YIAVILENFS VATEESAEPL
     SEDDFEMFYE VWEKFDPDAT QFMEFEKLSQ FAAALEPPLN LPQPNKLQLI AMDLPMVSGD
     RIHCLDILFA FTKRVLGESG EMDALRIQME ERFMASNPSK VSYQPITTTL KRKQEEVSAV
     IIQRAYRRHL LKRTVKQASF TYNKNKIKGG ANLLIKEDMI IDRINENSIT EKTDLTMSTA
     ACPPSYDRVT KPIVEKHEQE GKDEKAKGK
//
